Published in final edited form as:

J Med Chem. 2015 April 9; 58(7): 3002–3024. doi:10.1021/jm501440q.

Perturbation of the c-Myc–Max Protein–Protein Interaction via Synthetic α -Helix Mimetics

Kwan-Young Jung^a, Huabo Wang^b, Peter Teriete^c, Jeremy L. Yap^a, Lijia Chen^a, Maryanna E. Lanning^a, Angela Hu^a, Lester J. Lambert^c, Toril Holien^d, Anders Sundan^d, Nicholas Cosford^c, Edward V. Prochownik^b, and Steven Fletcher^{a,e,*}

^aDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N Pine Street, Baltimore, MD 21201

^bSection of Hematology/Oncology, Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC Pittsburgh, PA 15224

^cCell Death and Survival Networks Research Program, NCI-Designated Cancer Center, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA

KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

^eUniversity of Maryland Greenebaum Cancer Center, Baltimore, MD 21201

Abstract

The rational design of inhibitors of the bHLH-ZIP oncoprotein c-Myc is hampered by a lack of structure in its monomeric state. We describe herein the design of novel, low-molecular-weight, synthetic α -helix mimetics that recognize helical c-Myc in its transcriptionally active coiled-coil structure in association with its obligate bHLH-ZIP partner Max. These compounds perturb the heterodimer's binding to its canonical E-box DNA sequence without causing protein–protein dissociation, heralding a new mechanistic class of “direct” c-Myc inhibitors. This model was corroborated by additional biophysical methods including NMR spectroscopy and surface plasmon resonance. Several compounds demonstrated a 2-fold or greater selectivity for c-Myc–Max heterodimers over Max–Max homodimers with IC₅₀ values as low as 5.6 μ M. Finally, these compounds inhibited the proliferation of c-Myc-over-expressing cell lines in a concentration-dependent manner that correlated with the loss of expression of a c-Myc-dependent reporter plasmid despite the fact that c-Myc–Max heterodimers remained intact.

Graphical abstract

*CORRESPONDING AUTHOR. sfletcher@rx.umaryland.edu, Tel: 1-410-706-6361, Fax: 1-410-706-5017.

SUPPORTING INFORMATION AVAILABLE: Synthesis of intermediates **3e**, **3g**, **8**, **5g–5i**, **6e**, **10**, **21**, **22**, **26–28**, EMSA dose-response plots for **1aa**, **4da**, **1ca**, **12**, **13** and **18**, and cell cycle analysis data for **4da** and 10058-F4. This information if available free of charge via the internet at <http://pubs.acs.org>

Keywords

c-Myc; Max; Protein–Protein Interaction; α -Helix Mimetic; 10074-G5; JY-3-094; JKY-2-169; JQ-1

Introduction

c-Myc is a basic helix-loop-helix leucine zipper (bHLH-ZIP) transcription factor that, in addition to being oncogenic when over-expressed, affects many transformation-related processes such as proliferation, apoptosis, differentiation and metabolism.^{1–10} As an intrinsically disordered protein, c-Myc becomes transcriptionally functional only after heterodimerizing with its obligate bHLH-ZIP partner Max to assume a coiled-coil structure that recognizes the E-box sequence 5'-CACGTG-3'.¹¹ Indeed, this event is required for all known biological functions of c-Myc, including its oncogenic activity.^{1–5,12} c-Myc dysregulation is associated with most human cancers, including lung, pancreatic and colorectal cancers, as well as leukaemias and lymphomas,^{13–19} and numerous murine cancer models are c-Myc-dependent, even when c-Myc is not the primary oncogenic driver.^{20–22} Together, these studies suggest that c-Myc inhibition, either direct or indirect (for example, via inhibition of the BET bromodomains BRD2–4^{23–27}), is a viable therapeutic strategy towards the development of new and targeted antineoplastics. Indeed, both genetic and pharmacologic inhibition of c-Myc, or its closely-related cousin N-Myc, *in vivo* have resulted in tumour regression and prolonged survival.^{22,28,29} Moreover, despite the widespread expression of c-Myc by normal proliferating cells, recent studies have demonstrated that long-term, whole-body genetic silencing of c-Myc *in vivo* leads to remarkably mild and reversible side effects,^{30–33} providing further rationale that c-Myc inhibition is a clinically feasible strategy to expand the anti-cancer drug arsenal.

In contrast to the bromodomain proteins BRD2–4 that exhibit well-defined, acetyl-lysine binding sites that are tractable targets for small-molecule drug design and provide an indirect approach to the inhibition of oncogenic c-Myc function,^{23–27} the rational design of direct c-Myc inhibitors is complicated by the intrinsic disorder of the bHLH-ZIP domain, although some progress has been made.^{34–49} Several of the more potent compounds that have been identified bind to distinct segments of this region and cause highly localized distortions that prevent productive interaction with Max's bHLH-ZIP domain.^{45,46} For example, 10058-F4

(1) binds c-Myc_{402–410}, whilst 10074-G5 (2) binds c-Myc_{363–381}. However, these compounds generally exhibit only low affinities to c-Myc, double-digit micromolar IC₅₀ values for the prevention of c-Myc–Max heterodimerization *in vitro* and similar activities in cellular proliferation assays. Attempted optimizations of 2 (for example, JY-3-094 (3) and its ester prodrugs) and 10058-F4 have met with limited success, and new leads are urgently required. In contrast to monomeric c-Myc, the c-Myc–Max heterodimer exists as a structured coiled coil with ~70% α -helical content that increases to 84% upon DNA binding.⁵⁰ We, therefore, reasoned that molecules appropriately crafted to recognize this α -helical content might perturb the protein–protein interaction (PPI). Precedent for this approach has been described by Hamilton wherein synthetic α -helix mimetics have successfully disrupted the assembly of multiple helices involved in HIV-1 infection⁵¹ and abrogated the aggregation of transient helical forms of amyloid⁵² that would otherwise lead to amyloid fibrillogenesis. More generally, we^{53–55} and others^{56,57} have demonstrated that synthetic α -helix mimetics are effective inhibitors of a range of helix-mediated PPIs in which only one of the protein partners uses an α -helical recognition domain, including Bcl-x_L–Bak, Mcl-1–Bim and HDM2–p53.⁵⁸ In light of these observations, we hypothesized that rationally engineered α -helix mimetics might disrupt the coiled coil of the c-Myc–Max heterodimer, thus providing a novel therapeutic strategy to inhibit the oncogenic function of c-Myc.

Results

Design

We have previously shown there to be at least three independent small-molecule binding sites on the c-Myc bHLH-ZIP domain.^{45,46} We have also recently completed a structure–activity relationship (SAR) analysis of the direct c-Myc inhibitor 2,⁴⁷ which binds one of these sites centered around residues 363–381 corresponding to the junction between the basic domain and helix 1. NMR analysis of the interaction of 2 with a c-Myc_{363–381} synthetic peptide allowed the delineation of a more refined binding site, and our SAR work was largely in agreement with this model. Interestingly, NOESY experiments indicated that 2 induced helicity in the c-Myc_{363–381} peptide. The successful targeting of c-Myc_{363–381} with congeners of 2 coupled with c-Myc's acquisition of considerable helicity upon heterodimerization with Max suggests that synthetic α -helix mimetics designed to recognize this region of c-Myc in its helical form might perturb the c-Myc–Max heterodimer and impair DNA binding. This may be envisaged to occur either through directly interfering with the construction of the c-Myc–Max interface when c-Myc is mostly helical and complex formation is almost complete or through disruption of c-Myc's HLH motif within the c-Myc–Max heterodimer. Accordingly, we designed the α -helix mimetic 4 depicted in Figure 1A. Analogous to our oligoamide-based α -helix mimetics of the Bak-BH3 α -helix in which the side chains of each of the three subunits mimic the *i*, *i* + 3/4 and *i* + 7 side chains on one face of the native helix,⁵³ the hydrophobic R¹ and R² groups were designed to recognize Phe₃₇₄ (*i*) and Leu₃₇₇ (*i* + 3), respectively, of helical c-Myc in late stage complex assembly. Alternatively, these hydrophobic groups may recognize the tetramethylene side-chain of Lys₃₇₁ (*i*) and Phe₃₇₅ (*i* + 4) of the assembled complex. Since this hydrophobic domain is flanked by arginines Arg₃₆₆/Arg₃₆₇/Arg₃₇₂ and Arg₃₇₈ at the N- and C-terminal ends,

respectively, we incorporated groups into the periphery of **4** that would complement these basic side chains. For inspiration, we looked to previous small-molecules that also bind this region: the electron rich nitro group of **2** is believed to interact with Arg₃₆₆, Arg₃₆₇ and Arg₃₇₂,^{45,46} whereas the carboxylic acid in the second-generation **2** congener JY-3-094⁴⁷ possibly interacts with Arg₃₇₈. Since the nitro group of **2** and that of JY-3-094 along with its carboxylic acid were instrumental in furnishing the small-molecules with c-Myc inhibitory activities, we, therefore, selected a nitro group to recognize Arg₃₆₆, Arg₃₆₇ and/or Arg₃₇₂ and a carboxylic acid to recognize Arg₃₇₈. This would allow the bis-benzamides to be prepared from the readily available starting material 3-fluoro-4-nitrobenzoic acid (**2**). In addition, it was anticipated that the carboxylic acid would serve to promote the solubilities of the helix mimetics. A putative binding mode of target molecule **4da** ("JKY-2-169") is given in Figure 1B.

Chemistry

Target molecules **4** were readily generated in a short, convergent synthesis. Subunits were synthesized as described in Schemes 1 and 2. The benzene-based subunits were synthesized starting from 3-fluoro-4-nitrobenzoic acid (**5**). Nucleophilic aromatic substitution (S_NAr) reactions of **5** with either alcohols R¹OH or R²OH (R¹ and R² group identities given in Scheme 3) with an excess of NaH furnished the 3-alkoxy derivatives **6**. Treatment of acids **6** with oxalyl chloride delivered acid chlorides **7**, whilst reduction by catalytic hydrogenation or tin (II) chloride yielded anilines **8**. Esterification of acids **6** followed by nitro group reduction delivered anilines **9**. Two pyridine-based subunits were also prepared (Scheme 2). Briefly, 2,6-dichloro-3-nitropyridine (**10**) was regioselectively 2-isobutoxylated, and then the 6-chloro group was converted to a carboxylic acid (compound **11**) via a two-step Stille reaction with tributyl(vinyl)tin followed by oxidative cleavage of the newly installed vinyl group. Acid chloride generation or nitro group reduction as before then furnished subunits **12** and **13**, respectively. The bis-benzamides **4**, **14–16** were then prepared by condensations of acid chlorides **7** and **12** with anilines **8**, **9** and **13** in the presence of *N,N*-dimethylaniline as base (Scheme 3). In order to determine the importance of the R¹ and R² side-chains, bis-benzamides **4aj**, **4ja** and **4jj** were also prepared according to Scheme 3 but in which at least one of the subunits carried no side-chain (i.e. 4-aminobenzoic acid and/or 4-nitrobenzoyl chloride). To investigate the significance of the nitro group, 3-isobutoxybenzoyl chloride was coupled to 4-amino-3-isobutoxybenzoic acid (**8a**) to afford compound **17**, again essentially as described in Scheme 3. Additional analogues to test the importance of the nitro group were prepared as shown in Scheme 4. Specifically, the nitro group of compounds **16**, **4aa** and **4ea** was reduced with tin (II) chloride to deliver anilines **18**, **19** and **20**, respectively. Acylation of **19** with ethyl chlorooxoacetate or diglycolic anhydride generated compounds **21** and **22**, respectively, and then the former underwent saponification to deliver compound **23** as shown in Scheme 5. Modifications to the C-terminus are depicted in Scheme 6 where the proximity of the acidic group, as well as the number of acidic groups, would allow further investigation of the structure-activity relationships (SAR) of these compounds, as in compounds **26** and **27**. Finally, relocation of the side chains to the 2-position of the benzene ring was effected starting from commercially available compound **28** (Scheme 7).

Appropriate subunits (**4aa**, **30** and **31**) were then coupled together using similar chemistry to that described in Scheme 3 to afford target molecules **32–34**.

Biology

Initially, a focused library of derivatives of **4** was prepared, and the compounds were screened in an electrophoretic mobility shift assay (EMSA) at 100 μ M concentrations for their abilities to disrupt c-Myc–Max(S)/DNA complexes. The structures of these compounds are presented in Table 1 along with the EMSA screening results, where “0%” indicates complete disruption of the c-Myc–Max/DNA complex relative to the DMSO vehicle control (“100%”). Encouragingly, two compounds, **4aa** and **4da** (“**4da**”), from the initial batch of 10 derivatives of **4** demonstrated potent activity in this assay. In addition to **4aa** and **4da**, the next most active compound, **4bb**, also possesses an ionizable carboxylic acid. The remaining seven compounds are methyl ester derivatives and were largely inactive, thus indicating the important contribution of the carboxylic acid.

Given the promising EMSA screening data in Table 1, we expanded our library of c-Myc–Max disruptors. Although two methyl esters (**14ba** and **14ca**) demonstrated modest inhibitory activities, they exhibited poor solubilities. Hence, we focused largely on the preparation of only carboxylic acid-functionalized compounds; their structures are shown in Tables 2 and 3. All compounds in Table 2 exhibit a nitro group at the *N*-terminus, and either a carboxylic acid or a methyl ester at the *C*-terminus. In Table 3, these functional groups were varied somewhat. Also, the scaffold benzene rings were changed to pyridines and the positions of the side-chains was investigated. We again used an EMSA-based screening assay to evaluate the second group of helix mimetic-based putative c-Myc inhibitors (full structures in SI). From a total of 31 tested compounds, we identified an additional four inhibitors (**4ca**, **15**, **16** and **21**) that produced complete disruption of the c-Myc–Max/DNA binding at 100 μ M (Tables 2 and 3). Although this screen was performed only once, it is tempting to speculate that the nature and position of the hydrophobic side-chains are critical to activity (compare the data for **4ac**, **4ca** and **4jj**, and **4ca** with **4ga**, and also **4aa** with **32–34**). A carboxylic acid appears important at the *C*-terminus (for example, compare **4aa** and **14aa**), as does a nitro group at the *N*-terminus (for example, compare **4aa** with **17** and **19**, where the nitro group has been replaced with a hydrogen atom or an amino group, respectively). Finally, replacement of the scaffold benzene rings with more hydrophilic pyridines seems to be tolerated (compare **4aa** with **15** and **16**).

With the above screening data in hand, **4aa**, **4da**, **4ca**, **15**, **16** and **21** were evaluated in further detail by confirmatory EMSA analysis. Each compound demonstrated a dose-dependent inhibition of the c-Myc–Max(S)/DNA ternary complex with IC_{50} s < 50 μ M (Figure 2, Table 4). The most potent inhibitor **21** (IC_{50} = 5.6 μ M) displays an ethyl aminooxalate, indicating the nitro group in our original design of generic compound **4** is not critical for activity, provided a suitable bioisostere is present. To examine the specificity of these compounds, we also tested their abilities to disrupt DNA binding by Max homodimers in otherwise identical EMSA assays (Figure 2, Table 4). The foregoing experiments capitalized on the fact that the 151 residue “short” isoform of Max [Max(S)] only binds DNA as a heterodimer in association with c-Myc. In contrast, the 160 residue “Max(L)”

isoform also binds DNA as a homodimer and can therefore be used to assess the specificity of direct Myc inhibitors.^{59–61} In each case, the six helix mimetics exhibited a two-fold or greater selectivity for c-Myc–Max(S)/DNA complexes over Max(L)–Max(L)/DNA complexes thereby suggesting that these compounds recognize c-Myc rather than Max (Table 4).

4da recognizes the α -helical structure of c-Myc in the c-Myc–Max(S)

heterodimer—We next performed NMR experiments to further our understanding of the mechanism of **4da**'s inhibition at an atomic level. For this we utilized homogeneously pure, recombinant ¹⁵N-labeled or unlabeled c-Myc and Max(S) proteins. ¹⁵N-HSQC spectroscopy allows the observation of interactions between small molecules and a protein of interest over a broad range of affinities. Furthermore, even without residue-specific assignment, the technique provides insight into changes in secondary structures and potentially allows the elucidation of affinities. First, we examined the ability of **4da** to interact with the Max(S) homodimer or the c-Myc monomer (Figure 3A and B). Titration of the compound up to 100 μ M failed to reveal any observable chemical shift perturbations, thereby indicating that this compound does not bind either of the individual proteins. We then formed the c-Myc–¹⁵N-Max(S) heterodimer through the addition of an equimolar amount of unlabeled c-Myc to ¹⁵N-Max(S). This led to the expected substantial change in the HSQC spectrum of ¹⁵N-Max(S) (Figure 3C). Finally, addition of **4da** to the heterodimer led to further and substantial chemical shift perturbations, clearly indicating that the heterodimer is needed to provide a suitable binding site for this inhibitor and that, following **4da** addition, the final configuration attained is unlike that of either of the individual proteins alone (Figure 3D). Careful analysis of four isolated peaks suggested a $K_d \sim 13 \mu$ M for **4da** (Figure 3E).

This study conclusively shows that **4da** is unable to bind these proteins in either of their alternate conformations by themselves (c-Myc monomer or Max(S) homodimers), but clearly interacts with the c-Myc–Max heterodimer. This is particularly important in the case of the Max(S) homodimer, which has an α -helical structure that closely resembles that of the c-Myc–Max heterodimer.¹¹ The binding of **4da** to specific epitopes dictated by this heterodimer alters its structure in a manner that does not restore either of the spectra generated by the individual protein partners. Rather, the novel structure indicates that it remains in a heterodimeric form that is unable to bind DNA, as shown in Figure 3C.

Surface plasmon resonance (SPR) indicates 4da binds the c-Myc–Max(S)

heterodimer—We next utilized SPR to determine whether **4da** behaves in a manner distinct from that of previously described direct c-Myc inhibitors such as 10058-F4 and **2** which interfere with c-Myc–Max dimerization and DNA binding as a consequence of their efficient interaction with the unstructured c-Myc monomer, rendering it incapable of interacting with Max.³⁴ However, they are relatively inefficient at disrupting pre-formed dimers due to the high free energy of protein–protein association.^{34–38,45–49} An experimental outcome consistent with this previously proposed model is shown in Figure 4. After first establishing conditions under which c-Myc–Max(S) heterodimer binding to an E-box-containing oligonucleotide could be quantified (Figure 4A), we showed that **2** prevented c-Myc–Max(S) oligonucleotide binding significantly better if it was pre-incubated with c-

Myc monomer prior to the addition of Max(S) (Figure 4B vs. 4C). In contrast, while **4da** was also somewhat better at inhibiting DNA binding if added to c-Myc and Max(S) proteins prior to their heterodimerization, it was much more effective than **2** against pre-formed c-Myc–Max(S) heterodimers (Figure 4D and 4C). In light of our other findings reported herein, particularly those depicted in Figure 3, these results are most consistent with the idea that **4da**, rather than binding to the c-Myc monomer, preferentially interacts with the c-Myc–Max(S) heterodimer, alters its structure and renders it incapable of DNA binding without actually promoting its dissociation into c-Myc and Max(S) monomers.

4da inhibits c-Myc-overexpressing cells—The six active compounds described above were next investigated for their abilities to inhibit the proliferation of HL60 human promyelocytic leukaemia cells and Daudi Burkitt's lymphoma cells, both of which over-express c-Myc and are highly susceptible to various c-Myc inhibitors.^{37,38,45,48,49} As shown in Table 5, all compounds except **21** inhibited the proliferation of both cell lines with IC₅₀s below 50 μ M. Indeed, the HL60 inhibition data closely mirrored the *in vitro* data for inhibition of the c-Myc–Max(S)/DNA ternary complex. **4da** proved the most potent inhibitor of cell proliferation across both cell lines. It is unclear at this stage why compound **21** did not exhibit cell activity. Standard hydrolysis of the ethyl ester of **21** by cellular esterase will furnish the inactive compound **25**, whilst amide hydrolysis by peptidases will afford inactive compound **19**. Therefore, we hypothesize that metabolism of **21** to either **19** or **25** might explain the lack of cell activity.

Having established that **4da** was the most potent of the above compounds *in vitro* and in cells, we tested it further against several other cell lines (Table 6), including those representing epithelial cancers and several human multiple myeloma lines, the latter having previously been shown to be moderately sensitive to the growth inhibitory effects of the highly specific direct c-Myc inhibitor 10058-F4^{37,62} (IC₅₀s = 52–90 μ M. One of these myeloma lines, U266, expresses L-Myc instead of c-Myc and had previously been shown to be the least sensitive of all myeloma cell lines to growth inhibition by 10058-F4 (IC₅₀ ~100 μ M⁶²). We also tested **4da** against rat fibroblasts with a homozygous deletion of the endogenous *myc* gene (HO15.19 cells) as well as HO15.19 cells in which Myc expression had been restored by stable transduction with a c-Myc-expressing retroviral vector (HO15.19-wt-Myc cells).^{63,64} Consistent with the idea that **4da** is a specific c-Myc inhibitor, we found all c-Myc-expressing cell lines to be sensitive to relatively low concentrations of the compounds. However, U266 myeloma cells were the most resistant of the myeloma cell lines tested and HO15.19 fibroblasts were more resistant to **4da** than HO15.19-Myc cells. That both transformed and non-transformed cells were growth-inhibited by **4da** is consistent with the idea that c-Myc expression is necessary for the proliferation of virtually all cells and that c-Myc over-expression and/or de-regulation is not a pre-requisite for sensitivity to this class of inhibitors or to other modes of pharmacologic or genetically-mediated Myc inhibition in general.^{21,65} The residual susceptibilities of U266 and myeloma cells and HO15.19 suggests that **4da** may have additional targets that are necessary to support proliferation and/or non-specific toxicities.

4da promotes cell cycle arrest and accumulation of neutral lipids—The inhibition of c-Myc in proliferating cells, either *in vitro* or *in vivo*, leads to cell cycle arrest and eventual apoptosis.^{66,67} This induced quiescence is likely related to changes in cellular energy metabolism given the fact that c-Myc is intimately involved in supporting mitochondrial biogenesis and glycolysis.^{68–70} Indeed, c-Myc-depleted cells possess atrophic mitochondria and defective electron transport chain complexes as well as low levels of oxidative phosphorylation, glycolysis and ATP.^{68–70} Recently, Zirath *et al.* have shown that N-Myc-amplified neuroblastoma cells accumulate stores of neutral lipid following their exposure to the small-molecule c-Myc inhibitor 10058-F4,²⁸ and we have made similar findings in *myc*–/– fibroblasts.⁷¹ We have shown this to result from an increase in the transport of exogenous very long chain fatty acids that represents a compensatory attempt to fuel the TCA cycle with substrates other than glucose or glutamine, whose utilization by the TCA cycle is compromised in c-Myc-depleted cells. However, because of the defective mitochondrial structure and function, the uptake of these fatty acids exceeds their utilization and the difference is stored as neutral lipid.

To determine whether our synthetic α -helix mimetics imitated the above-described phenotypes associated with c-Myc depletion, we treated HL60 promyelocytic leukemia cells and H460 large cell lung cancer cells with **4da**, and then evaluated the cells for evidence of proliferative arrest and neutral lipid accumulation, respectively. As positive controls for these studies, parallel cultures were treated with the previously well-characterized direct Myc inhibitors 10058-F4 or **2**.³⁷ As seen in Figure 5, both 10058-F4 and **4da** promoted a G0/G1 arrest in HL60 cells, with the latter compound being both more efficient and potent. Repeat experiments performed on different occasions yielded very similar results (Supplementary Table 1). Similarly, treatment of H460 cells with both **2** and **4da** led to an increase in neutral lipid stores, with **4da** again being more effective (Figure 6). From these studies, we conclude that these structurally unrelated c-Myc inhibitors exert similar effects on proliferation and cellular energetics.

4da specifically inhibits a c-Myc-dependent reporter—To determine whether, as previously described for 10058-F4,⁷² **4da** specifically inhibited c-Myc-dependent genes, we stably transfected HeLa cells with a vector encoding a highly labile luciferase protein. The minimal promoter of this vector was engineered to contain tandemly triplicated binding sites for c-Myc (wt-Myc) or NF- κ B. Control vectors contained either no binding sites or mutant c-Myc binding sites (mut-Myc) (CTCGAG rather than the canonical CACGTG). Relative to the latter control lines whose expression of luciferase was indistinguishable from the background of untransfected cells, the luciferase activities in cells expressing the wt-c-Myc and NF- κ B vectors were 10–20 times and 100–200 times, respectively, higher than the background. As seen in Figure 7, both **4da** and the control direct c-Myc inhibitor showed a dose-dependent inhibition of luciferase in cells expressing the wt-c-Myc vector, whereas no inhibition of luciferase was observed in cells expressing the NF- κ B vector. From these studies, we conclude that **2** and **4da** selectively suppress the expression of genes containing c-Myc binding sites, with the latter compound again being more potent.

4da does not disrupt c-Myc–Max heterodimers in cells—The foregoing studies, particularly those shown in Figure 3 suggested that, while **4da** was specific for c-Myc, its mechanism of action was distinct from that of previously described direct Myc inhibitors which prevent/disrupt Myc–Max association.³⁴ To further confirm that **4da** did not promote c-Myc–Max dissociation, we exposed HL60 cells to concentrations of the compound shown in the above studies to inhibit cell cycle progression, proliferation and Myc-specific gene expression and then performed c-Myc–Max co-IP studies. As a positive control, a parallel culture of cells was exposed to the compound 10058-F4, at a concentration previously shown to disrupt c-Myc–Max heterodimers.³⁸ As shown in Figure 8, 10058-F4 treatment abrogated c-Myc's association with Max, in a dose-dependent manner, without significantly affecting the overall level of the former protein. In contrast, c-Myc–Max heterodimers remain largely intact following exposure to even the highest levels of **4da**. Taken together with the studies shown in Figure 2, these findings provide independent confirmation that **4da**, while inhibiting a variety of c-Myc-regulated functions, does so without promoting c-Myc–Max dissociation.

Discussion

Synthetic α -helix mimetics have been successfully utilized in the past to interrogate and disrupt aberrant helix-mediated PPIs.^{51–58} The transcriptionally active c-Myc–Max coiled coil presents itself as a potential target that might be disrupted or otherwise perturbed by such agents. We designed biphenyl-based α -helix mimetics that, along with a hydrophobic core and electron-rich peripheries, were intended to recognize a hydrophobic domain of helical c-Myc flanked by arginines and other polar residues, specifically the region R₃₆₆RNELKRSFFALR₃₇₈, that ensures the formation of a rigid tertiary structure upon dimerizing with Max. Importantly, this would represent an unprecedented strategy to inhibit the oncogenic activity of c-Myc since those direct inhibitors that have been fully characterized to date operate through binding and stabilizing the unstructured c-Myc monomer, rendering it incapable of interacting with Max.³⁵

Several of the compounds reported herein impaired the ability of the c-Myc–Max(S) dimer to recognize its DNA-binding sequence, as shown by EMSA. To delineate the mode of inhibition of the synthetic helix mimetics, we recruited an array of biophysical techniques. HSQC NMR spectroscopy employing ¹⁵N-labeled Max(S) indicated that the helix mimetic **4da** interacted only with c-Myc–Max(S) heterodimers and not with Max(S)–Max(S) homodimers or c-Myc monomers. This allowed us to infer that the biological target is the c-Myc–Max(S) heterodimer exclusively. Furthermore, according to NMR titrations, **4da** bound helical c-Myc with a K_d of approximately 13 μ M. These findings were further corroborated by SPR, which was consistent with the idea that **4da** binds the c-Myc–Max heterodimer and alters its structure such that DNA binding is impaired. Indeed, the K_d for this interaction, ca. 10 μ M (Figure 4D), is in excellent agreement with that obtained by NMR (K_d ~13 μ M (Figure 2E)). The somewhat higher K_d obtained under conditions in which c-Myc–Max(S) heterodimers were allowed to pre-form before the addition of **4da** (Figure 4E) suggests that the heterodimer is more stable under these conditions. This could be explained by assuming that, in the initial stages of heterodimerization, the helix 1 regions of c-Myc and Max(S) may assemble into a structure that is recognized by **4da**, as originally

proposed in the design section, before the remaining regions of the proteins have the opportunity to fully assemble into their final and most stable conformations. Such a partially formed heterodimer might be more readily distorted by **4da**.

SPR alone cannot directly discriminate between a mechanism that distorts the c-Myc–Max(S) heterodimer as proposed here for **4da** and one that prevents c-Myc–Max(S) interaction. However, the markedly different behaviors in response to **2** and **4da** (Figure 5), together with the results of our NMR studies (Figure 3) argue strongly in favor of the former model to explain **4da**'s mechanism of action. Moreover, they are consistent with our inability to demonstrate disruption of c-Myc–Max heterodimers with **4da** by *in situ* co-immunoprecipitation under conditions where it can be readily demonstrated by inhibitors that directly bind the c-Myc monomer, such as 10058-F4, **2** or their analogues.^{37,38,47–49} The helix mimetics reported herein inhibited the proliferation of c-Myc-overexpressing cells in a manner that reflected their abilities to disrupt DNA binding by the c-Myc–Max heterodimer *in vitro*. Finally, the induction of cell cycle arrest, the accumulation of neutral lipids and the inhibition of c-Myc-dependent gene expression, are all consistent with c-Myc being the main cellular target of **4da** and other such compounds. Nonetheless, **4da** may possess some non-specific toxicities or recognize other targets that are needed to drive proliferation as evidenced by the inhibition of some cell lines that do not express c-Myc (Table 6). It will be important to minimize such properties in future attempts to optimize this class of compounds. It is tempting to speculate that compounds such as **4da** might be particularly effective in conjunction with other direct inhibitors such as 10058-F4 and **2** by preventing or reversing DNA binding by any residual c-Myc–Max(S) heterodimers that formed in the presence of the latter compounds.

Conclusions

Novel, direct inhibitors of c-Myc were designed based on a synthetic α -helix mimetic strategy to recognize and perturb the structure of the coiled coil c-Myc–Max heterodimer. Our most potent compound, **4da**, demonstrated this activity *in vitro* with IC₅₀ values in the low micromolar range. Several techniques were enlisted to delineate the mechanism of inhibition of our compounds. The outcomes of these studies are consistent with the idea that, as designed, these compounds bind helical c-Myc, and impair the c-Myc–Max heterodimer's ability to bind DNA without causing the dissociation of c-Myc–Max heterodimers. The *in vitro* results were mirrored by studies showing that under conditions where **4da** inhibited cell growth, c-Myc–Max heterodimers remained intact *in situ*. Current work is focused on determining the metabolic stability of **4da**, since the c-Myc inhibitor **2** exhibits a short half-life due to metabolism of the nitro group to the toxic hydroxylamino derivative and the inactive amino-derivative.⁷³ Hence, in addition to contributing to a short half-life, the nitro group in **4da** may also be responsible for the general toxicity of the compound. Thus, towards the further optimization of our helix mimetics, efforts will be made to seek out nitro group bioisosteres, of which it is already known there exists at least one (ethyl aminooxalate in compound **21**). More generally, the identification of a new mechanism of action by which direct c-Myc inhibitors may function should provide ample opportunities for the design of

novel analogues of compounds such as those described here that are intended to promote more efficient cellular uptake and PPI disruption.

EXPERIMENTAL

Chemistry: General

Unless otherwise stated, all reactions were performed under an inert (N_2) atmosphere. Reagents and solvents were reagent grade and purchased from Sigma-Aldrich, Alfa Aesar, Oakwood and TCI America. Anhydrous solvents were purchased from Sigma-Aldrich and used as provided. Reactions were monitored by TLC, visualizing with a UV lamp and/or $KMnO_4$ stain. Silica gel 60 (70–230 mesh, Merck) was used for flash column chromatography. 1H and ^{13}C NMR spectra were recorded on Varian INOVA 400 MHz NMR spectrometers at 25 °C. Chemical shifts are reported in parts per million (ppm). Data for 1H NMR are reported as follows: chemical shift (δ ppm) (integration, multiplicity, coupling constant (Hz), identity). Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, hep = heptet, dd = doublet of doublets, m = multiplet. Data for ^{13}C are reported in terms of chemical shifts (δ ppm). The residual solvent peak was used as an internal reference. The mass spectra were obtained on an Electrospray TOF (ESI-TOF) mass spectrometer (BrukerAmaZon X). Target molecules that were evaluated beyond the initial EMSA screen (**4aa**, **4da**, **4ca**, **15**, **16** and **21**) exhibited purities of >95% as determined by CHN elemental combustion analysis.

General procedure A: Nucleophilic aromatic substitution (S_NAr)—NaH (3 eq) was suspended in anhydrous THF (0.1 M), and the requisite alcohol (1.3 eq) was added at 0 °C under an inert (N_2) atmosphere. After 15 min, 3-fluoro-4-nitrobenzoic acid (1 eq) was added. The reaction mixture was stirred for 15 min at 0 °C, then at RT for 2 h. TLC indicated the reaction was complete. The reaction was quenched by adding sat. NH_4Cl , then partitioned with EtOAc. The aqueous layer was put to one side, and then the organic layer was washed twice with 0.1 M HCl. The organic layer was dried over Na_2SO_4 , filtered, concentrated and purified by flash column chromatography over silica gel using an eluent of Hex/EtOAc/AcOH, 1:1:0.1 to provide the title compound.

General Procedure B: Acid chloride synthesis—To a solution of the carboxylic acid in CH_2Cl_2 or THF (0.1 M) at 0 °C was added dropwise oxalyl chloride followed by one drop of DMF. The reaction was stirred under an inert atmosphere at room temperature for 2 h (typically, all reactions were complete after this time), and then concentrated *in vacuo* and dried for at least 5 h under high vacuum to afford the acid chloride which was used without further purification.

General Procedure C: Reduction of nitro group with Pd/C—10% Pd/C (20wt%) was carefully added to an evacuated flask of the nitro compound in EtOH (0.1 M). H_2 was bubbled through the reaction mixture for 10 min, then the reaction was stirred under 1 atm of H_2 (balloon) for 1 – 5 h. TLC confirmed the reaction was complete. The reaction mixture was filtered over Celite, washing with MeOH. The filtrate was concentrated *in vacuo*, then dried under high vacuum to furnish the title compound.

General Procedure D: Reduction of nitro group with $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ —The nitro compound (1 eq) was dissolved in EtOAc (0.1 M), and then $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (5 eq) was added. The reaction mixture was stirred for 3 h at 50 °C, by which time TLC confirmed the reaction was complete. The reaction mixture was partitioned between EtOAc and sat. NaHCO_3 . The organic layer was collected and the aqueous layer was extracted with further EtOAc ($\times 2$). The organic layers were combined, washed with sat. NaHCO_3 , brine, dried (Na_2SO_4), filtered and concentrated. The residue was purified by silica gel flash column chromatography using a gradient of EtOAc in Hex as eluent to furnish the corresponding aniline.

General procedure E: Methyl ester hydrolysis— NaOH (4 eq) was added to a solution of the methyl ester (1 eq) in a 3:1:1 mixture of THF/MeOH/ H_2O (0.08 M). The reaction was stirred at room temperature until complete consumption of the starting material (1 h – 4 d). The reaction mixture was diluted with further water, acidified to pH 5 with 1N HCl and then extracted into EtOAc ($\times 5$). The organic layers were combined, dried over Na_2SO_4 , filtered and concentrated to give the carboxylic acid which did not require further purification.

General procedure F: Bis-arylamide synthesis—To a solution of the aniline (1 eq) and *N,N*-dimethylaniline in anhydrous acetone (0.2 M) at 0 °C was added dropwise a solution of the acid chloride of the appropriate 4-nitrobenzoic acid (1 eq) in anhydrous acetone (0.2 M). The resulting mixture was allowed to warm to room temperature overnight. The white precipitate was collected by vacuum filtration, washed with acetone, 2N HCl, and water until the filtrate was neutral, and then dried *in vacuo* at 40 °C overnight.

3-Isobutoxy-4-(3-isobutoxy-4-nitrobenzamido)benzoic acid (4aa): 3-Isobutoxy-4-nitrobenzoic acid⁷⁴ (**6a**) was converted to its corresponding acid chloride according to General Procedure B on a 0.33 mmol scale, then coupled to 4-amino-3-isobutoxybenzoic acid⁷⁴ (**8a**) according to General Procedure F to deliver the title compound as a pale yellow solid (80 mg, 56%): $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz) δ 12.98 (1H, s, CO_2H), 9.79 (1H, s, NH), 8.03 (1H, d, $J=8.0$ Hz, Ar), 7.97 (1H, d, $J=8.0$ Hz, Ar), 7.79 (1H, s, Ar), 7.62 (2H, d, $J=8.0$ Hz, Ar), 7.57 (1H, s, Ar), 4.03 (2H, d, $J=6.4$ Hz, OCH_2), 3.89 (2H, d, $J=6.4$ Hz, OCH_2), 2.08 (2H, m, $2\times\text{CH}(\text{CH}_3)_2$), 0.99 (12H, m, $2\times\text{CH}(\text{CH}_3)_2$); $^{13}\text{C-NMR}$ (DMSO-d_6 , 100 MHz) δ 167.3, 163.9, 151.4, 150.8, 141.5, 139.7, 131.2, 128.5, 125.5, 123.7, 122.3, 119.9, 114.2, 112.9, 75.6, 74.9, 28.2, 28.0, 19.4, 19.1; MS (ESI) m/z Calcd for $\text{C}_{22}\text{H}_{26}\text{N}_2\text{O}_7$ (M^+): 430.2, Found: 431.1 ($\text{M}+\text{H}^+$); Anal. Calcd for $\text{C}_{22}\text{H}_{26}\text{N}_2\text{O}_7$: C, 61.39; H, 6.09; N, 6.51. Found: C, 61.11; H, 6.07; N, 6.37.

3-(Benzyloxy)-4-(3-isobutoxy-4-nitrobenzamido)benzoic acid (4ac): 3-Isobutoxy-4-nitrobenzoic acid⁷⁴ (**6a**) was converted to its corresponding acid chloride according to General Procedure B on a 0.19 mmol scale, then coupled to 4-amino-3-benzyloxybenzoic acid⁷⁵ (**8c**) according to General Procedure F to deliver the title compound as a pale yellow solid (46 mg, 52%): $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz) δ 12.96 (1H, s, CO_2H), 9.91 (1H, s, NH), 7.99 (1H, d, $J=8.0$ Hz, Ar), 7.91 (1H, d, $J=8.0$ Hz, Ar), 7.74 (1H, s, Ar), 7.65 (1H, s, Ar), 7.59 (2H, t, $J=8.4$ Hz, Ar), 7.50 (2H, d, $J=6.8$ Hz, Ar), 7.34 (2H, t, $J=6.8$ Hz, Ar), 7.30

(1H, d, J=6.8 Hz, Ar), 5.24 (2H, s, OCH₂), 3.96 (2H, d, J=5.6 Hz, OCH₂), 2.01 (1H, m, CH(CH₃)₂), 0.95 (6H, d, J=6.4 Hz, CH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 167.2, 164.1, 151.5, 150.6, 141.5, 139.7, 137.1, 131.4, 128.8, 128.6, 128.2, 127.6, 125.4, 124.3, 122.6, 120.0, 114.3, 113.7, 75.6, 70.3, 28.0, 19.1; MS (ESI) *m/z* Calcd for C₂₅H₂₄N₂O₇ (M⁺): 464.2, Found: 465.1 (M+H⁺).

4-(3-Isobutoxy-4-nitrobenzamido)-3-(pyridin-2-ylmethoxy)benzoic acid (4ag): 3-Isobutoxy-4-nitrobenzoic acid⁷⁴ (**6a**) was converted to its corresponding acid chloride according to General Procedure B on a 0.24 mmol scale, then coupled to 4-amino-3-(pyridin-2-ylmethoxy)benzoic acid (**8g**) according to General Procedure F to deliver the title compound as a white solid (55 mg, 49%): ¹H-NMR (DMSO-d₆, 400 MHz) δ 12.99 (1H, s, CO₂H), 10.19 (1H, s, NH), 8.06 (1H, d, J=8.0 Hz, Ar), 8.02 (1H, d, J=8.0 Hz, Ar), 7.82 (2H, m, Py), 7.68 (3H, m, Ar+Py), 7.61 (1H, d, J=8.0 Hz, Ar), 7.35 (1H, t, J=4.8 Hz, Py), 5.37 (2H, s, OCH₂), 4.02 (2H, d, J=6.4 Hz, OCH₂), 2.05 (1H, m, CH(CH₃)₂), 0.99 (6H, d, J=6.0 Hz, CH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 167.1, 164.1, 156.7, 151.5, 150.2, 149.4, 141.6, 139.7, 137.4, 131.9, 128.4, 125.5, 123.9, 123.5, 123.2, 121.8, 119.9, 114.7, 114.5, 75.6, 71.8, 28.0, 19.1; MS (ESI) *m/z* Calcd for C₂₄H₂₃N₃O₇ (M⁺): 465.2, Found: 466.1 (M+H⁺).

4-(3-Isobutoxy-4-nitrobenzamido)-3-(pyridin-3-ylmethoxy)benzoic acid (4ah): 3-Isobutoxy-4-nitrobenzoic acid⁷⁴ (**6a**) was converted to its corresponding acid chloride according to General Procedure B on a 0.37 mmol scale, then coupled to 4-amino-3-(pyridin-3-ylmethoxy)benzoic acid (**8h**) according to General Procedure F to deliver the title compound as a white solid (120 mg, 70%): ¹H-NMR (DMSO-d₆, 400 MHz) δ 13.01 (1H, bs, CO₂H), 10.01 (1H, s, NH), 8.94 (1H, s, Py), 8.71 (1H, d, J=4.0 Hz, Py), 8.35 (1H, d, J=8.0 Hz, Ar), 8.00 (1H, d, J=8.4 Hz, Ar), 7.91 (1H, d, J=8.0 Hz, Py), 7.77 (2H, m, Ar+Py), 7.69 (1H, s, Ar), 7.65 (1H, d, J=8.0 Hz, Ar), 7.61 (1H, d, J=8.4 Hz, Ar), 5.41 (2H, s, OCH₂), 3.98 (2H, d, J=6.4 Hz, OCH₂), 2.02 (1H, m, CH(CH₃)₂), 0.96 (6H, d, J=6.8 Hz, CH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 167.1, 164.2, 151.5, 150.3, 145.4, 144.7, 141.5, 140.5, 139.6, 135.2, 131.4, 128.7, 125.7, 125.4, 124.7, 123.0, 120.1, 114.5, 113.7, 75.6, 67.4, 28.0, 19.1; MS (ESI) *m/z* Calcd for C₂₄H₂₃N₃O₇ (M⁺): 465.2, Found: 466.1 (M+H⁺).

4-(3-Isobutoxy-4-nitrobenzamido)-3-(pyridin-4-ylmethoxy)benzoic acid (4ai): 3-Isobutoxy-4-nitrobenzoic acid⁷⁴ (**6a**) was converted to its corresponding acid chloride according to General Procedure B on a 0.28 mmol scale, then coupled to 4-amino-3-(pyridin-4-ylmethoxy)benzoic acid (**8i**) according to General Procedure F to deliver the title compound as a white solid (94 mg, 72%): ¹H-NMR (DMSO-d₆, 400 MHz) δ 13.00 (1H, bs, CO₂H), 10.27 (1H, s, NH), 8.87 (2H, d, J=5.6 Hz, Py), 8.06 (2H, d, J=5.6 Hz, Py), 8.02 (1H, d, J=8.8 Hz, Ar), 7.87 (2H, d, J=8.4 Hz, Ar), 7.66 (3H, m, Ar), 5.58 (2H, s, OCH₂), 4.01 (2H, d, J=5.6 Hz, OCH₂), 2.02 (1H, m, CH(CH₃)₂), 0.96 (6H, d, J=6.0 Hz, CH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 166.9, 164.1, 155.6, 151.4, 150.1, 143.4, 141.5, 139.4, 131.2, 128.8, 125.3, 125.2, 123.9, 123.1, 120.0, 114.5, 113.6, 75.6, 68.1, 27.9, 19.0; MS (ESI) *m/z* Calcd for C₂₄H₂₃N₃O₇ (M⁺): 465.2, Found: 466.1 (M+H⁺).

4-(3-Isobutoxy-4-nitrobenzamido)benzoic acid (4aj): 3-Isobutoxy-4-nitrobenzoic acid⁷⁴ (**6a**) was converted to its corresponding acid chloride according to General Procedure B on a 0.31 mmol scale, then coupled to 4-aminobenzoic acid (**8j**) according to General Procedure F to deliver the title compound as a pale yellow solid (76 mg, 69%): ¹H-NMR (DMSO-d₆, 400 MHz) δ 12.78 (1H, s, CO₂H), 10.65 (1H, s, NH), 8.00 (1H, d, J=8.8 Hz, Ar), 7.94 (2H, d, J=8.8 Hz, Ar), 7.87 (2H, d, J=8.8 Hz, Ar), 7.76 (1H, s, Ar), 7.61 (1H, d, J=8.0 Hz, Ar), 4.02 (2H, d, J=6.0 Hz, OCH₂), 2.03 (1H, m, CH(CH₃)₂), 0.97 (6H, d, J=6.4 Hz, CH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 167.3, 164.7, 151.4, 143.1, 141.5, 140.1, 130.7, 126.4, 125.3, 120.1, 114.7, 75.7, 28.1, 19.1; MS (ESI) *m/z* Calcd for C₁₈H₁₈N₂O₆ (M⁺): 358.1, Found: 359.1 (M+H⁺).

3-Isopropoxy-4-(3-isopropoxy-4-nitrobenzamido)benzoic acid (4bb): 3-Isopropoxy-4-nitrobenzoic acid⁵³ (**6b**) was converted to its corresponding acid chloride according to General Procedure B on a 0.31 mmol scale, then coupled to 4-amino-3-isopropoxybenzoic acid⁷⁴ (**8b**) according to General Procedure F to deliver the title compound as a pale yellow solid (38 mg, 31%): ¹H-NMR (CDCl₃+CD₃OD, 400 MHz) δ 8.44 (1H, s, NH), 7.80 (2H, d, J=8.0 Hz, Ar), 7.59 (2H, s, 2xAr-1H), 7.27 (2H, d, J=8.0 Hz, Ar), 4.73 (2H, m, 2xOCH(CH₃)₂), 1.38 (12H, d, J=5.2 Hz, 2xOCH(CH₃)₂); ¹³C-NMR (CDCl₃+CD₃OD, 100 MHz) δ 163.0, 151.4, 145.7, 142.7, 139.3, 131.7, 125.7, 118.5, 117.1, 115.2, 73.0, 71.6, 29.6, 22.0, 21.7; MS (ESI) *m/z* Calcd for C₂₀H₂₂N₂O₇ (M⁺): 402.1, Found: 403.0 (M+H⁺).

3-Isobutoxy-4-(3-benzyloxy-4-nitrobenzamido)benzoic acid (4ca): 3-Benzyloxy-4-nitrobenzoic acid⁷⁵ (**6c**) was converted to its corresponding acid chloride according to General Procedure B on a 0.37 mmol scale, then coupled to 4-amino-3-isobutyroxybenzoic acid⁷⁵ (**8a**) according to General Procedure F to deliver the title compound as a pale yellow solid (68 mg, 40%): ¹H-NMR (DMSO-d₆, 400 MHz) δ 12.98 (1H, s, CO₂H), 9.82 (1H, s, NH), 8.07 (1H, d, J=8.0 Hz, Ar), 7.94 (2H, m, Ar), 7.66 (1H, d, J=8.0 Hz, Ar), 7.62 (1H, d, J=8.0 Hz, Ar), 7.57 (1H, s, Ar), 7.46-7.41 (4H, m, Ar), 7.38 (1H, d, J=6.4 Hz, Ar), 5.40 (2H, s, OCH₂), 3.89 (2H, d, J=5.6 Hz, OCH₂), 2.07 (1H, m, CH(CH₃)₂), 0.99 (6H, d, J=6.4 Hz, CH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 167.3, 163.9, 151.0, 150.9, 141.8, 139.7, 136.1, 131.1, 129.0, 128.6, 127.8, 125.6, 123.9, 122.3, 120.2, 115.0, 113.0, 74.9, 71.2, 28.1, 19.4; MS (ESI) *m/z* Calcd for C₂₅H₂₄N₂O₇ (M⁺): 464.2, Found: 465.1 (M+H⁺); Anal. Calcd for C₂₅H₂₄N₂O₇: C, 64.65; H, 5.21; N, 6.03. Found: C, 64.86; H, 5.23; N, 6.06.

3-Isobutoxy-4-(3-(naphthalen-1-ylmethoxy)-4-nitrobenzamido)benzoic acid (4da (“JKY-2-169”)): 3-Naphthalen-1-ylmethoxy-4-nitrobenzoic acid⁷⁵ (**6d**) was converted to its corresponding acid chloride according to General Procedure B on a 0.31 mmol scale, then coupled to 4-amino-3-isobutyroxybenzoic acid⁷⁴ (**8a**) according to General Procedure F to deliver the title compound as a pale yellow solid (134 mg, 84%): ¹H-NMR (DMSO-d₆, 400 MHz) δ 12.96 (1H, s, CO₂H), 9.80 (1H, s, NH), 8.14 (1H, s, Ar), 8.07 (1H, d, J=7.2 Hz, Ar), 8.04 (1H, d, J=8.0 Hz, Ar), 7.96-7.92 (3H, m, Ar), 7.69 (1H, d, J=7.2 Hz, Ar), 7.65 (1H, d, J=8.0 Hz, Ar), 7.60-7.50 (5H, m, Ar), 5.82 (2H, s, OCH₂), 3.85 (2H, d, J=5.6 Hz, OCH₂), 2.04 (1H, m, CH(CH₃)₂), 0.95 (6H, d, J=6.0 Hz, CH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 167.3, 164.0, 151.1, 150.8, 141.8, 139.8, 133.6, 131.6, 131.2, 129.4, 128.9, 128.5, 126.9, 126.8, 126.5, 125.8, 125.6, 124.1, 123.8, 122.3, 120.3, 115.0, 112.9, 74.9, 69.8, 28.1,

19.4; MS (ESI) m/z Calcd for $C_{29}H_{26}N_2O_7$ (M^+): 514.2, Found: 515.1 ($M+H^+$); Anal. Calcd for $C_{29}H_{26}N_2O_7$: C, 67.70; H, 5.09; N, 5.44. Found: C, 67.41; H, 4.94; N, 5.35.

4-(3-((2,3-Dihydro-1H-inden-2-yl)oxy)-4-nitrobenzamido)-3-isobutoxybenzoic acid (4ea): 3-(2,3-dihydro-1H-inden-2-yl)oxy-4-nitrobenzoic acid (**6e**) was converted to its corresponding acid chloride according to General Procedure B on a 0.66 mmol scale, then coupled to 4-amino-3-isobutoxybenzoic acid⁷⁵ (**8a**) according to General Procedure F to deliver the title compound as a pale yellow solid (252 mg, 78%): 1H -NMR (DMSO- d_6 , 400 MHz) δ 12.95 (1H, s, CO_2H), 9.79 (1H, s, NH), 7.98 (1H, d, $J=8.4$ Hz, Ar), 7.95 (1H, d, $J=8.4$ Hz, Ar), 7.87 (1H, s, Ar), 7.59 (2H, m, Ar), 7.54 (1H, s, Ar), 7.23 (2H, m, Ar), 7.16 (2H, m, Ar), 5.50 (1H, m, OCH), 3.86 (2H, d, $J=6.4$ Hz, OCH_2), 3.45 (2H, dd, $J=6.0$ Hz, 17.2 Hz, $CHCH_2$), 3.08 (2H, d, $J=17.2$ Hz, $CHCH_2$), 2.06 (1H, m, $CH(CH_3)_2$), 0.97 (6H, d, $J=6.0$ Hz, $CH(CH_3)_2$); ^{13}C -NMR (DMSO- d_6 , 100 MHz) δ 167.3, 164.0, 150.9, 150.2, 142.3, 140.5, 139.6, 131.2, 128.5, 127.1, 125.7, 125.0, 123.9, 122.3, 120.2, 115.1, 112.9, 80.3, 74.9, 28.3, 19.4; MS (ESI) m/z Calcd for $C_{27}H_{26}N_2O_7$ (M^+): 490.2, Found: 491.1 ($M+H^+$).

3-Methoxy-4-(3-methoxy-4-nitrobenzamido)benzoic acid (4ff): 3-Methoxy-4-nitrobenzoic acid (**6f**) was converted to its corresponding acid chloride according to General Procedure B on a 0.49 mmol scale, then coupled to 4-amino-3-methoxybenzoic acid (**8f**) according to General Procedure F to deliver the title compound as a pale yellow solid (129 mg, 76%): 1H -NMR (DMSO- d_6 , 400 MHz) δ 12.99 (1H, s, CO_2H), 9.92 (1H, s, NH), 8.02 (1H, d, $J=8.0$ Hz, Ar), 7.95 (1H, d, $J=8.0$ Hz, Ar), 7.83 (1H, s, Ar), 7.65-7.60 (3H, m, Ar), 4.02 (3H, s, OCH_3), 3.91 (3H, s, OCH_3); ^{13}C -NMR (DMSO- d_6 , 100 MHz) δ 167.3, 164.2, 152.0, 151.3, 141.4, 139.8, 131.0, 128.4, 125.4, 124.0, 122.3, 120.1, 114.0, 112.1, 57.3, 56.3; MS (ESI) m/z Calcd for $C_{16}H_{14}N_2O_7$ (M^+): 346.1, Found: 347.0 ($M+H^+$).

3-Isobutoxy-4-(4-nitro-3-(pyridin-2-ylmethoxy)benzamido)benzoic acid (4ga): 4-Nitro-3-(pyridin-2-ylmethoxy)benzoic acid (**6g**) was converted to its corresponding acid chloride according to General Procedure B on a 0.20 mmol scale, then coupled to 4-amino-3-isobutoxybenzoic acid⁷⁵ (**8a**) according to General Procedure F to deliver the title compound as a white solid (72 mg, 77%): 1H -NMR (DMSO- d_6 , 400 MHz) δ 13.00 (1H, s, CO_2H), 9.85 (1H, s, NH), 8.61 (1H, s, Ar), 8.11 (1H, d, $J=8.0$ Hz, Ar), 7.97 (1H, s, Ar), 7.93-7.89 (2H, m, Ar+Py), 7.69 (1H, d, $J=8.4$ Hz, Ar), 7.63 (1H, d, $J=8.4$ Hz, Ar), 7.58 (2H, m, Py), 7.39 (1H, t, $J=6.0$ Hz, Py), 5.49 (2H, s, OCH_2), 3.89 (2H, d, $J=5.2$ Hz, OCH_2), 2.07 (1H, m, $CH(CH_3)_2$), 0.99 (6H, d, $J=6.0$ Hz, $CH(CH_3)_2$); ^{13}C -NMR (DMSO- d_6 , 100 MHz) δ 167.3, 163.8, 155.8, 151.0, 150.9, 149.6, 141.6, 139.8, 137.6, 131.1, 128.6, 125.8, 124.1, 123.6, 122.3, 121.7, 120.5, 114.9, 113.0, 74.9, 71.8, 28.1, 19.4; MS (ESI) m/z Calcd for $C_{24}H_{23}N_3O_7$ (M^+): 465.2, Found: 466.1 ($M+H^+$).

3-Isobutoxy-4-(4-nitrobenzamido)benzoic acid (4ja): 4-Nitrobenzoyl chloride (**7j**; 0.45 mmol) was coupled to 4-amino-3-isobutoxybenzoic acid⁷⁴ (**8a**) according to General Procedure F to deliver the title compound as a white solid (154 mg, 96%): 1H -NMR (DMSO- d_6 , 400 MHz) δ 12.94 (1H, s, CO_2H), 9.85 (1H, s, NH), 8.35 (2H, d, $J=8.4$ Hz, Ar), 8.13 (2H, d, $J=8.4$ Hz, Ar), 7.88 (1H, d, $J=7.6$ Hz, Ar), 7.58 (1H, d, $J=7.6$ Hz, Ar), 7.53 (1H, s, Ar), 3.85 (2H, d, $J=6.4$ Hz, OCH_2), 2.03 (1H, m, $CH(CH_3)_2$), 0.95 (6H, d, $J=6.4$ Hz,

CH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 167.3, 164.0, 151.0, 149.7, 140.4, 131.2, 129.4, 128.6, 124.2, 124.1, 122.2, 113.0, 74.9, 28.1, 19.4; MS (ESI) *m/z* Calcd for C₁₈H₁₈N₂O₆ (M⁺): 358.1, Found: 359.1 (M+H⁺).

4-(4-Nitrobenzamido)benzoic acid (4jj): 4-Nitrobenzoyl chloride (**7j**; 0.693 mmol) was coupled to 4-aminobenzoic acid according to General Procedure F to deliver the title compound as a pale yellow solid (180 mg, 91%): ¹H-NMR (DMSO-d₆, 400 MHz) δ 12.81 (1H, s, CO₂H), 10.85 (1H, s, NH), 8.40 (2H, d, J=8.4 Hz, Ar), 8.21 (2H, d, J=8.4 Hz, Ar), 7.99 (2H, d, J=8.4 Hz, Ar), 7.93 (2H, d, J=8.4 Hz, Ar); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 167.3, 164.7, 149.7, 143.2, 140.6, 130.7, 129.7, 126.4, 124.0, 120.1; MS (ESI) *m/z* Calcd for C₁₄H₁₀N₂O₅ (M⁺): 286.1, Found: 287.0 (M+H⁺).

Methyl 3-isobutoxy-4-(3-isobutoxy-4-nitrobenzamido)benzoate (14aa): 3-Isobutoxy-4-nitrobenzoic acid⁷⁴ (**6a**) was converted to its corresponding acid chloride according to General Procedure B on a 0.18 mmol scale, then coupled to methyl 4-amino-3-isobutoxybenzoate⁷⁴ (**9a**) according to General Procedure F to deliver the title compound as a pale yellow solid (51 mg, 64%): ¹H-NMR (CDCl₃, 400 MHz) δ 8.78 (1H, s, NH), 8.60 (1H, d, J=8.4 Hz, Ar), 7.93 (1H, d, J=8.4 Hz, Ar), 7.75 (1H, d, J=8.4 Hz, Ar), 7.64 (1H, s, Ar), 7.58 (1H, s, Ar), 7.39 (1H, d, J=8.4 Hz, Ar), 3.95 (4H, m, 2xOCH₂), 3.92 (3H, s, OCH₃), 2.18 (2H, m, 2xCH(CH₃)₂), 1.11 (6H, d, J=6.4 Hz, CH(CH₃)₂), 1.07 (6H, d, J=6.4 Hz, CH(CH₃)₂); ¹³C-NMR (CDCl₃, 100 MHz) δ 166.5, 163.0, 152.8, 147.0, 141.6, 139.7, 131.4, 125.9, 125.8, 123.3, 118.6, 117.2, 113.7, 111.5, 76.0, 75.0, 52.1, 28.2, 28.1, 19.3, 18.9; MS (ESI) *m/z* Calcd for C₂₃H₂₈N₂O₇ (M⁺): 444.2, Found: 445.1 (M+H⁺).

Methyl 3-isobutoxy-4-(3-isopropoxy-4-nitrobenzamido)benzoate (14ba): 3-Isopropoxy-4-nitrobenzoic acid⁵³ (**6b**) was converted to its corresponding acid chloride according to General Procedure B on a 0.18 mmol scale, then coupled to methyl 4-amino-3-isobutoxybenzoate⁷⁴ (**9a**) according to General Procedure F to deliver the title compound as a pale yellow solid (77 mg, 100%): ¹H-NMR (CDCl₃, 400 MHz) δ 8.76 (1H, s, NH), 8.59 (1H, d, J=8.4 Hz, Ar), 7.86 (1H, d, J=8.4 Hz, Ar), 7.75 (1H, d, J=8.4 Hz, Ar), 7.67 (1H, s, Ar), 7.57 (1H, s, Ar), 7.36 (1H, d, J=8.4 Hz, Ar), 4.80 (1H, m, OCH(CH₃)₂), 3.94-3.91 (5H, m, OCH₃+OCH₂CH), 2.19 (1H, m, CH₂CH(CH₃)₂), 1.43 (6H, d, J=5.6 Hz, OCH(CH₃)₂), 1.10 (6H, d, J=7.2 Hz, CH₂CH(CH₃)₂); ¹³C-NMR (CDCl₃, 100 MHz) δ 166.5, 163.1, 151.5, 147.0, 142.8, 139.4, 131.4, 125.7, 123.3, 118.6, 117.0, 115.3, 111.5, 75.1, 73.0, 52.1, 28.2, 21.7, 19.3; MS (ESI) *m/z* Calcd for C₂₂H₂₆N₂O₇ (M⁺): 430.2, Found: 431.1 (M+H⁺).

Methyl 3-(benzyloxy)-4-(3-isopropoxy-4-nitrobenzamido)benzoate (14bc): 3-Isopropoxy-4-nitrobenzoic acid⁵³ (**6b**) was converted to its corresponding acid chloride according to General Procedure B on a 0.16 mmol scale, then coupled to methyl 4-amino-3-benzyloxybenzoate⁷⁵ (**9c**) according to General Procedure F to deliver the title compound as a pale yellow solid (71 mg, 96%): ¹H-NMR (CDCl₃, 400 MHz) δ 8.72 (1H, s, NH), 8.60 (1H, d, J=8.4 Hz, Ar), 7.78 (1H, d, J=8.4 Hz, Ar), 7.74 (1H, d, J=8.4 Hz, Ar), 7.71 (1H, s, Ar), 7.54 (1H, s, Ar), 7.42-7.40 (5H, m, Ar), 7.23 (1H, d, J=8.4 Hz, Ar), 5.19 (2H, s, OCH₂), 4.63 (1H, m, OCH), 3.90 (3H, s, OCH₃), 1.34 (6H, d, J=5.6 Hz, CH(CH₃)₂); ¹³C-NMR (CDCl₃, 100 MHz) δ 166.7, 163.3, 151.6, 147.2, 143.0, 139.3, 135.9, 131.9, 129.1, 129.0,

128.2, 125.9, 124.1, 119.0, 117.7, 115.3, 112.6, 73.2, 71.8, 52.4, 21.9; MS (ESI) m/z Calcd for $C_{25}H_{24}N_2O_7$ (M^+): 464.2, Found: 465.1 ($M+H^+$).

Methyl 3-benzyloxy-4-(3-isobutoxy-4-nitrobenzamido)benzoate (14ca): 3-

Benzyloxy-4-nitrobenzoic acid⁷⁵ (**6c**) was converted to its corresponding acid chloride according to General Procedure B on a 0.18 mmol scale, then coupled to methyl 4-amino-3-isobutoxybenzoate⁷⁴ (**9a**) according to General Procedure F to deliver the title compound as a pale yellow solid (86 mg, 100%): ¹H-NMR ($CDCl_3$, 400 MHz) δ 8.77 (1H, s, NH), 8.54 (1H, d, $J=8.4$ Hz, Ar), 7.94 (1H, d, $J=8.4$ Hz, Ar), 7.61 (1H, s, Ar), 7.73 (1H, d, $J=8.4$ Hz, Ar), 7.56 (1H, s, Ar), 7.46-7.30 (5H, m, Ar), 5.27 (2H, s, OCH_2), 3.92-3.89 (5H, m, OCH_3+OCH_2CH), 2.18 (1H, m, $CH_2CH(CH_3)_2$), 1.08 (6H, d, $J=7.2$ Hz, $CH_2CH(CH_3)_2$); ¹³C-NMR ($CDCl_3$, 100 MHz) δ 166.6, 162.9, 152.1, 147.1, 141.9, 139.7, 134.8, 131.3, 128.7, 128.4, 127.0, 126.0, 125.8, 123.2, 118.7, 117.6, 114.6, 111.6, 75.1, 71.3, 52.2, 28.2, 19.2; MS (ESI) m/z Calcd for $C_{26}H_{26}N_2O_7$ (M^+): 478.2, Found: 479.1 ($M+H^+$).

Methyl 4-(3-((2,3-dihydro-1H-inden-2-yl)oxy)-4-nitrobenzamido)-3-

isobutoxybenzoate (14ea): 3-((2,3-dihydro-1H-inden-2-yl)oxy)-4-nitrobenzoic acid (**6e**) was converted to its corresponding acid chloride according to General Procedure B on a 0.18 mmol scale, then coupled to methyl 4-amino-3-isobutoxybenzoate⁷⁴ (**9a**) according to General Procedure F to deliver the title compound as a yellow solid (85 mg, 94%): ¹H-NMR ($CDCl_3$, 400 MHz) δ 8.80 (1H, s, NH), 8.61 (1H, d, $J=8.4$ Hz, Ar), 7.90 (1H, d, $J=8.4$ Hz, Ar), 7.77 (2H, d, $J=10.0$ Hz, Ar), 7.59 (1H, s, Ar), 7.40 (1H, d, $J=8.4$ Hz, Ar), 7.26-7.19 (4H, m, Ar), 5.38 (1H, m, OCH), 3.95 (2H, d, $J=6.4$ Hz, OCH_2CH), 3.92 (3H, s, OCH_3), 3.52 (2H, dd, $J=6.4$ Hz, 16.8 Hz, $CHCH_2$), 3.30 (2H, dd, $J=6.4$ Hz, 16.8 Hz, $CHCH_2$), 2.21 (1H, m, $CH_2CH(CH_3)_2$), 1.10 (6H, d, $J=6.4$ Hz, $CH_2CH(CH_3)_2$); ¹³C-NMR ($CDCl_3$, 100 MHz) δ 166.5, 162.9, 151.5, 147.0, 142.4, 139.6, 139.5, 131.3, 127.0, 126.0, 125.8, 124.6, 123.3, 118.6, 117.2, 115.0, 111.6, 80.2, 75.1, 52.2, 39.5, 28.2, 19.3; MS (ESI) m/z Calcd for $C_{28}H_{28}N_2O_7$ (M^+): 504.2, Found: 505.1 ($M+H^+$).

Methyl 3-(benzyloxy)-4-(3-benzyloxy-4-nitrobenzamido)benzoate (14cc): 3-

Benzyloxy-4-nitrobenzoic acid⁷⁵ (**6c**) was converted to its corresponding acid chloride according to General Procedure B on a 0.16 mmol scale, then coupled to methyl 4-amino-3-benzyloxybenzoate⁷⁵ (**9c**) according to General Procedure F to deliver the title compound as a pale yellow solid (67 mg, 82%): ¹H-NMR ($CDCl_3$, 400 MHz) δ 8.73 (1H, s, NH), 8.58 (1H, d, $J=8.4$ Hz, Ar), 7.83 (1H, d, $J=8.4$ Hz, Ar), 7.77 (1H, d, $J=8.4$ Hz, Ar), 7.71 (1H, s, Ar), 7.64 (1H, s, Ar), 7.44-7.32 (10H, m, Ar), 7.25 (1H, d, $J=8.4$ Hz, Ar), 5.19 (2H, s, OCH_2), 5.16 (2H, s, OCH_2), 3.91 (3H, s, OCH_3); ¹³C-NMR ($CDCl_3$, 100 MHz) δ 166.7, 163.0, 152.3, 147.2, 142.2, 139.6, 135.9, 135.0, 131.9, 129.2, 129.0, 128.7, 128.1, 127.4, 126.1, 124.1, 119.1, 118.3, 114.6, 112.7, 71.8, 71.5, 52.5; MS (ESI) m/z Calcd for $C_{29}H_{24}N_2O_7$ (M^+): 512.2, Found: 513.1 ($M+H^+$).

Methyl 4-(3-(benzyloxy)-4-nitrobenzamido)-3-((2,3-dihydro-1H-inden-2-yl)oxy)benzoate (14ce): 3-Benzyloxy-4-nitrobenzoic acid⁷⁵ (**6c**) was converted to its

corresponding acid chloride according to General Procedure B on a 0.14 mmol scale, then

coupled to methyl 4-amino-3-((2,3-dihydro-1*H*-inden-2-yl)oxy)-benzoic acid (**9e**) according to General Procedure F to deliver the title compound as a pale yellow solid (69 mg, 92%): ¹H-NMR (CDCl₃, 400 MHz) δ 8.54 (1H, d, J=8.0 Hz, Ar), 8.42 (1H, d, NH), 7.77 (2H, m, Ar), 7.62 (2H, m, Ar), 7.43 (2H, d, J=8.0 Hz, Ar), 7.37 (2H, d, J=8.0 Hz, Ar), 7.32 (1H, d, J=8.0 Hz, Ar), 7.29 (2H, m, Ar), 7.20 (2H, m, Ar), 6.41 (1H, dd, J=1.6 Hz, 8.4 Hz, Ar), 5.40 (1H, t, J=5.2 Hz, OCH), 5.21 (2H, s, OCH₂), 3.92 (3H, s, OCH₃), 3.34 (2H, dd, J=5.2 Hz, 16.8 Hz, CHCH₂), 3.17 (2H, d, J=16.8 Hz, CHCH₂); ¹³C-NMR (CDCl₃, 100 MHz) δ 166.4, 162.7, 151.9, 145.1, 141.7, 140.2, 139.2, 134.8, 133.5, 128.7, 128.4, 127.1, 125.8, 125.0, 124.3, 118.8, 117.2, 115.3, 114.6, 80.8, 71.2, 52.2, 39.5; MS (ESI) *m/z* Calcd for C₃₁H₂₆N₂O₇ (M⁺): 538.2, Found: 539.1 (M+H⁺).

Methyl 3-isobutoxy-4-(3-(naphthalen-1-ylmethoxy)-4-nitrobenzamido)benzoate

(14da): 3-Naphthalen-1-ylmethoxy-4-nitrobenzoic acid⁷⁵ (**6d**) was converted to its corresponding acid chloride according to General Procedure B on a 0.18 mmol scale, then coupled to methyl 4-amino-3-isobutoxybenzoate⁷⁴ (**9a**) according to General Procedure F to deliver the title compound as a pale yellow solid (95 mg, 100%): ¹H-NMR (CDCl₃, 400 MHz) δ 8.79 (1H, s, NH), 8.60 (1H, d, J=8.4 Hz, Ar), 8.05 (1H, d, J=8.4 Hz, Ar), 7.95 (2H, t, J=8.4 Hz, Ar), 7.88 (2H, t, J=9.2 Hz, Ar), 7.76 (1H, d, J=9.2 Hz, Ar), 7.71 (1H, d, J=6.8 Hz, Ar), 7.60-7.47 (4H, m, Ar), 7.41 (1H, d, J=6.8 Hz, Ar), 5.75 (2H, s, OCH₂), 3.94-3.92 (5H, m, OCH₃+OCH₂CH), 2.19 (1H, m, CH₂CH(CH₃)₂), 1.09 (6H, d, J=6.4 Hz, CH₂CH(CH₃)₂); ¹³C-NMR (CDCl₃, 100 MHz) δ 166.5, 162.8, 152.2, 147.0, 142.0, 139.7, 133.6, 131.3, 130.9, 130.1, 129.4, 128.7, 126.7, 126.3, 126.1, 125.8, 125.3, 123.3, 123.1, 118.6, 117.6, 114.7, 111.6, 75.1, 70.1, 52.2, 28.2, 19.3; MS (ESI) *m/z* Calcd for C₃₀H₂₈N₂O₇ (M⁺): 528.2, Found: 529.1 (M+H⁺).

Methyl 3-(benzyloxy)-4-(3-(naphthalen-1-ylmethoxy)-4-nitrobenzamido)benzoate

(14dc): 3-(Naphthalen-1-ylmethoxy)-4-nitrobenzoic acid (**6d**) was converted to its corresponding acid chloride according to General Procedure B on a 0.16 mmol scale, then coupled to methyl 4-amino-3-benzyloxy-benzoic acid⁷⁵ (**9c**) according to General Procedure F to deliver the title compound as a pale yellow solid (40 mg, 45%): ¹H-NMR (CDCl₃, 400 MHz) δ 8.76 (1H, s, NH), 8.56 (1H, d, J=8.4 Hz, Ar), 7.97 (1H, d, J=8.0 Hz, Ar), 7.86-7.95 (4H, m, Ar), 7.76 (1H, d, J=8.4 Hz, Ar), 7.69 (1H, s, Ar), 7.60 (1H, d, J=6.8 Hz, Ar), 7.50 (2H, d, J=8.4 Hz, Ar), 7.45 (1H, d, J=8.4 Hz, Ar), 7.40 (2H, d, J=6.8 Hz, Ar), 7.32 (2H, t, J=8.4 Hz, Ar), 7.24 (2H, t, J=6.4 Hz, Ar), 5.52 (2H, s, OCH₂), 5.16 (2H, s, OCH₂), 3.89 (3H, s, OCH₃); ¹³C-NMR (CDCl₃, 100 MHz) δ 166.8, 163.2, 163.1, 152.3, 147.2, 142.2, 139.6, 135.8, 133.9, 131.8, 131.2, 130.3, 129.7, 129.1, 128.9, 128.1, 126.9, 126.8, 126.3, 126.1, 125.5, 124.1, 123.5, 119.2, 119.1, 118.3, 114.6, 112.7, 71.8, 70.3, 52.5; MS (ESI) *m/z* Calcd for C₃₃H₂₆N₂O₇ (M⁺): 562.2, Found: 563.1 (M+H⁺).

Methyl 3-((2,3-dihydro-1*H*-inden-2-yl)oxy)-4-(3-(naphthalen-1-ylmethoxy)-4-nitrobenzamido)benzoate (14de): 3-(Naphthalen-1-ylmethoxy)-4-nitrobenzoic acid⁷⁵ (**6d**) was converted to its corresponding acid chloride according to General Procedure B on a 0.14 mmol scale, then coupled to methyl 4-amino-3-((2,3-dihydro-1*H*-inden-2-yl)oxy)-benzoic acid (**9e**) according to General Procedure F to deliver the title compound as a pale yellow solid (60 mg, 73%): ¹H-NMR (CDCl₃, 400 MHz) δ 8.56 (1H, d, J=8.4 Hz, Ar), 8.44 (1H, s,

NH), 8.02 (1H, d, J=8.4 Hz, Ar), 7.87 (1H, d, J=8.0 Hz, Ar), 7.84 (1H, d, J=8.0 Hz, Ar), 7.79 (3H, m, Ar), 7.63 (2H, t, J=8.4 Hz, Ar), 7.57 (1H, t, J=8.4 Hz, Ar), 7.50 (1H, d, J=8.4 Hz, Ar), 7.46 (1H, d, J=8.0 Hz, Ar), 7.24 (2H, m, Ar), 7.15 (2H, m, Ar), 6.42 (1H, dd, J=1.6 Hz, 8.4 Hz, Ar), 5.65 (2H, s, OCH₂), 5.40 (1H, t, J=5.2 Hz, OCH), 3.92 (3H, s, OCH₃), 3.33 (2H, dd, J=4.8 Hz, 17.2 Hz, CHCH₂), 3.17 (2H, d, J=17.2 Hz, CHCH₂); ¹³C-NMR (CDCl₃, 100 MHz) δ 166.4, 162.7, 151.9, 145.1, 141.8, 140.2, 139.2, 133.6, 133.5, 130.9, 130.2, 129.4, 128.7, 127.1, 126.6, 126.4, 126.1, 125.9, 125.2, 125.0, 124.3, 123.2, 118.8, 117.3, 115.3, 114.7, 80.8, 70.0, 52.2, 39.5; MS (ESI) *m/z* Calcd for C₃₅H₂₈N₂O₇ (M⁺): 588.2, Found: 589.1 (M+H⁺).

Methyl 3-((2,3-dihydro-1H-inden-2-yl)oxy)-4-(3-isopropoxy-4-nitrobenzamido)benzoate (14eb): 3-Isopropoxy-4-nitrobenzoic acid⁵³ (**6b**) was converted to its corresponding acid chloride according to General Procedure B on a 0.14 mmol scale, then coupled to methyl 4-amino-3-((2,3-dihydro-1H-inden-2-yl)oxy)-benzoic acid (**9e**) according to General Procedure F to deliver the title compound as a pale yellow solid (60 mg, 87%): ¹H-NMR (CDCl₃, 400 MHz) δ 8.55 (1H, d, J=8.0 Hz, Ar), 8.43 (1H, s, NH), 7.77 (2H, m, Ar), 7.53 (2H, m, Ar), 7.28-7.25 (2H, m, Ar), 7.22-7.19 (2H, m, Ar), 6.38 (1H, dd, J=6.8 Hz, 0.8 Hz, Ar), 5.40 (1H, t, J=5.2 Hz, OCH), 4.69 (1H, m, OCH), 3.92 (3H, s, OCH₃), 3.35 (2H, dd, J=5.2 Hz, 16.8 Hz, CHCH₂), 3.18 (2H, d, J=16.8 Hz, CHCH₂), 1.37 (6H, d, J=6.4 Hz, CH(CH₃)₂); ¹³C-NMR (CDCl₃, 100 MHz) δ 166.4, 163.0, 151.3, 145.1, 142.6, 140.2, 138.8, 133.5, 127.1, 125.7, 125.5, 125.0, 124.2, 118.8, 116.6, 115.3, 115.1, 80.6, 72.8, 52.2, 39.5, 21.7; MS (ESI) *m/z* Calcd for C₂₇H₂₆N₂O₇ (M⁺): 490.2, Found: 491.1 (M+H⁺).

Methyl 3-(benzyloxy)-4-(3-((2,3-dihydro-1H-inden-2-yl)oxy)-4-nitrobenzamido)benzoate (14ec): 3-((2,3-Dihydro-1H-inden-2-yl)oxy)-4-nitrobenzoic acid (**6e**) was converted to its corresponding acid chloride according to General Procedure B on a 0.14 mmol scale, then coupled to methyl 4-amino-3-benzyloxy-benzoic acid⁷⁵ (**9c**) according to General Procedure F to deliver the title compound as a pale yellow solid (67 mg, 78%): ¹H-NMR (CDCl₃, 400 MHz) δ 8.77 (1H, s, NH), 8.61 (1H, d, J=7.6 Hz, Ar), 7.78 (2H, d, J=8.4 Hz, Ar), 7.72 (1H, s, Ar), 7.60 (1H, s, Ar), 7.42 (2H, d, J=7.6 Hz, Ar), 7.34 (3H, m, Ar), 7.25 (1H, d, J=7.6 Hz, Ar), 7.22 (3H, m, Ar), 5.19-5.17 (3H, m, OCH₂+OCH), 3.91 (3H, s, OCH₃), 3.38 (2H, dd, J=6.8 Hz, 17.2 Hz, CHCH₂), 3.21 (2H, dd, J=2.4 Hz, 17 Hz, CHCH₂); ¹³C-NMR (CDCl₃, 100 MHz) δ 166.7, 163.1, 151.6, 147.2, 142.6, 139.9, 139.4, 135.8, 131.9, 129.1, 128.2, 127.2, 126.2, 124.9, 124.1, 119.1, 118.0, 114.8, 112.6, 80.4, 71.8, 52.5, 39.8; MS (ESI) *m/z* Calcd for C₃₁H₂₆N₂O₇ (M⁺): 538.2, Found: 539.1 (M+H⁺).

Methyl 3-((2,3-dihydro-1H-inden-2-yl)oxy)-4-(3-((2,3-dihydro-1H-inden-2-yl)oxy)-4-nitrobenzamido)benzoate (14ee): 3-((2,3-Dihydro-1H-inden-2-yl)oxy)-benzoic acid (**6e**) was converted to its corresponding acid chloride according to General Procedure B on a 0.14 mmol scale, then coupled to methyl 4-amino-3-((2,3-dihydro-1H-inden-2-yl)oxy)-benzoic acid (**9e**) according to General Procedure F to deliver the title compound as a pale yellow solid (30 mg, 40%): ¹H-NMR (CDCl₃, 400 MHz) δ 8.57 (1H, d, J=8.4 Hz, Ar), 8.47 (1H, s, NH), 7.78 (2H, d, J=8.0 Hz, Ar), 7.62 (1H, s, Ar), 7.58 (1H, d, J=8.0 Hz, Ar), 7.27 (2H, m,

Ar), 7.20-7.16 (6H, m, Ar), 6.41 (1H, dd, $J=1.6$ Hz, 8.8 Hz, Ar), 5.42 (1H, m, OCH), 5.27 (1H, m, OCH), 3.92 (3H, s, OCH₃), 3.43 (2H, dd, $J=6.8$ Hz, 16.8 Hz, CHCH₂), 3.19 (2H, dd, $J=6.8$ Hz, 16.8 Hz, CHCH₂), 3.24-3.14 (4H, m, 2xCHCH₂); ¹³C-NMR (CDCl₃, 100 MHz) δ 166.4, 162.8, 151.2, 145.1, 142.2, 140.2, 139.6, 138.9, 133.5, 127.1, 126.9, 125.8, 125.0, 124.6, 124.3, 118.8, 116.9, 115.1, 115.0, 80.6, 80.1, 52.2, 39.5; MS (ESI) m/z Calcd for C₃₃H₂₈N₂O₇ (M⁺): 564.2, Found: 565.1 (M+H⁺).

3-Isobutoxy-4-(6-isobutoxy-5-nitropicolinamido)benzoic acid (15): 6-Isobutoxy-5-nitropicolinic acid (**11**) was converted to its corresponding acid chloride according to General Procedure B on a 0.41 mmol scale, then coupled to 4-amino-3-isobutoxybenzoic acid⁷⁵ (**6a**) according to General Procedure F to deliver the title compound as a pale yellow solid (156 mg, 88%): ¹H-NMR (DMSO-d₆, 400 MHz) δ 12.94 (1H, s, CO₂H), 10.22 (1H, s, NH), 8.67 (1H, d, $J=8.8$ Hz, Py), 8.54 (1H, d, $J=8.8$ Hz, Py), 7.95 (1H, d, $J=8.4$ Hz, Ar), 7.65 (1H, d, $J=8.4$ Hz, Ar), 7.58 (1H, s, Ar), 4.35 (2H, d, $J=5.6$ Hz, OCH₂), 3.98 (2H, d, $J=6.4$ Hz, OCH₂), 2.12 (2H, m, 2xCH(CH₃)₂), 1.04 (12H, m, 2xCH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 166.7, 159.8, 154.5, 149.5, 147.4, 137.3, 136.2, 130.3, 126.7, 122.5, 118.4, 115.8, 111.9, 74.7, 73.3, 27.8, 27.5, 19.1, 18.8; MS (ESI) m/z Calcd for C₂₁H₂₅N₃O₇ (M⁺): 431.2, Found: 432.1 (M+H⁺)⁺; Anal. Calcd for C₂₁H₂₅N₃O₇: C, 58.46; H, 5.84; N, 9.74. Found: C, 58.37; H, 5.84; N, 9.58.

6-Isobutoxy-5-(6-isobutoxy-5-nitropicolinamido)picolinic acid (16): 6-Isobutoxy-5-nitropicolinic acid (**11**) was converted to its corresponding acid chloride according to General Procedure B on a 0.41 mmol scale, then coupled to 6-isobutoxy-5-aminopicolinic acid (**13**) according to General Procedure F to deliver the title compound as a pale yellow solid (115 mg, 65%): ¹H-NMR (DMSO-d₆, 400 MHz) δ 12.97 (1H, s, CO₂H), 10.03 (1H, s, NH), 8.71 (1H, d, $J=7.6$ Hz, Py), 8.62 (1H, d, $J=7.6$ Hz, Py), 7.88 (1H, d, $J=7.6$ Hz, Py), 7.73 (1H, d, $J=7.6$ Hz, Py), 4.29 (2H, d, $J=5.2$ Hz, OCH₂), 4.19 (2H, d, $J=6.8$ Hz, OCH₂), 2.09 (2H, m, 2xCH(CH₃)₂), 1.00 (12H, m, 2xCH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 165.7, 160.8, 154.9, 152.6, 149.3, 139.8, 137.8, 136.7, 126.1, 125.0, 120.0, 116.2, 73.8, 73.1, 27.9, 19.6, 19.2; MS (ESI) m/z Calcd for C₂₀H₂₄N₄O₇ (M⁺): 432.2, Found: 433.1 (M+H⁺)⁺; Anal. Calcd for C₂₀H₂₄N₄O₇: C, 55.55; H, 5.59; N, 12.96. Found: C, 55.72; H, 5.49; N, 12.97.

3-Isobutoxy-4-(3-isobutoxybenzamido)benzoic acid (17): 3-Isobutoxy-benzoic acid was converted to its corresponding acid chloride according to General Procedure B on a 0.26 mmol scale, then coupled to 4-amino-3-isobutoxybenzoic acid⁷⁵ (**8a**) according to General Procedure F to deliver the title compound as a white solid (43 mg, 43%): ¹H-NMR (DMSO-d₆, 400 MHz) δ 12.97 (1H, s, CO₂H), 9.41 (1H, s, NH), 8.08 (1H, d, $J=8.0$ Hz, Ar), 7.61 (1H, d, $J=8.0$ Hz, Ar), 7.55 (1H, s, Ar), 7.50-7.43 (3H, m, Ar), 7.18 (1H, d, $J=6.8$ Hz, Ar), 3.90 (2H, d, $J=6.4$ Hz, OCH₂), 3.83 (2H, d, $J=6.4$ Hz, OCH₂), 2.12-2.03 (2H, m, CH(CH₃)₂), 1.03-0.99 (12H, m, 2xCH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 167.3, 165.0, 159.2, 149.9, 136.1, 131.7, 130.3, 127.7, 122.5, 122.4, 119.9, 118.9, 113.1, 112.6, 74.8, 74.3, 28.2, 28.1, 19.4; MS (ESI) m/z Calcd for C₂₂H₂₇NO₅ (M⁺): 385.2, Found: 386.1 (M+H⁺).

5-(5-Amino-6-isobutoxyypicolinamido)-6-isobutoxyypicolinic acid (18): 6-Isobutoxy-5-(6-isobutoxy-5-nitropicolinamido)picolinic acid (**16**; 40 mg, 0.093 mmol) was reduced according to General Procedure C: pale yellow solid (30 mg, 81%): ¹H-NMR (DMSO-d₆, 400 MHz) δ 9.96 (1H, s, NH), 8.70 (1H, d, J=7.6 Hz, Py), 7.64 (1H, d, J=7.6 Hz, Py), 7.58 (1H, d, J=7.6 Hz, Py), 6.96 (1H, d, J=7.6 Hz, Py), 5.87 (2H, s, NH₂), 4.20 (2H, d, J=6.4 Hz, OCH₂), 4.12 (2H, d, J=6.4 Hz, OCH₂), 2.11 (2H, m, 2xCH(CH₃)₂), 1.03 (6H, d, J=6.4 Hz, CH(CH₃)₂), 1.00 (6H, d, J=6.4 Hz, CH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 166.8, 163.1, 152.0, 150.0, 137.7, 131.7, 124.8, 119.2, 118.8, 117.7, 72.7, 71.9, 28.1, 28.0, 19.6; MS (ESI) *m/z* Calcd for C₂₀H₂₆N₄O₅ (M⁺): 402.2, Found: 403.1 (M+H⁺).

4-(4-Amino-3-isobutoxybenzamido)-3-isobutoxybenzoic acid (19): 3-Isobutoxy-4-(3-isobutoxy-4-nitrobenzamido)benzoic acid (**4aa**; 200 mg, 0.46 mmol) was reduced according to General Procedure C: pale yellow solid (184 mg, 100%): ¹H-NMR (DMSO-d₆, 400 MHz) δ 8.93 (1H, s, NH), 8.18 (1H, d, J=8.4 Hz, Ar), 7.55 (1H, d, J=8.4 Hz, Ar), 7.50 (1H, s, Ar), 7.32 (1H, d, J=8.4 Hz, Ar), 7.26 (1H, s, Ar), 6.68 (1H, d, J=7.6 Hz, Ar), 5.44 (2H, s, NH₂), 3.88 (2H, d, J=6.4 Hz, OCH₂), 3.76 (2H, d, J=6.4 Hz, OCH₂), 2.10 (2H, m, 2xCH(CH₃)₂), 1.00 (12H, m, 2x CH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 167.6, 164.8, 148.5, 145.1, 142.5, 132.0, 122.6, 121.7, 121.2, 120.3, 112.7, 112.3, 110.2, 74.8, 74.4, 28.2, 19.6, 19.5; MS (ESI) *m/z* Calcd for C₂₂H₂₈N₂O₅ (M⁺): 400.2, Found: 401.1 (M+H⁺).

4-(4-Amino-3-((2,3-dihydro-1H-inden-2-yl)oxy)benzamido)-3-isobutoxybenzoic acid (20): 4-(3-((2,3-Dihydro-1H-inden-2-yl)oxy)-4-nitrobenzamido)-3-isobutoxybenzoic acid (**4ea**; 60 mg, 0.12 mmol) was reduced according to General Procedure C: pale yellow solid (55 mg, 100%): ¹H-NMR (DMSO-d₆, 400 MHz) δ 8.97 (1H, s, NH), 8.17 (1H, d, J=8.0 Hz, Ar), 7.56 (1H, d, J=8.0 Hz, Ar), 7.51 (1H, s, Ar), 7.40 (1H, s, Ar), 7.33 (1H, d, J=8.0 Hz, Ar), 7.23 (2H, m, Ar), 7.15 (2H, m, Ar), 6.67 (1H, d, J=8.4 Hz, Ar), 5.38 (2H, s, NH₂), 5.22 (1H, m, OCH), 3.87 (2H, d, J=6.0 Hz, OCH₂), 3.40 (2H, dd, J=6.0 Hz, 17.2 Hz, CHCH₂), 3.12 (2H, d, J=16.4 Hz, CHCH₂), 2.10 (1H, m, CH(CH₃)₂), 0.99 (6H, d, J=7.2 Hz, CH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 164.9, 148.8, 143.6, 143.2, 141.0, 126.9, 125.0, 122.6, 121.8, 121.2, 120.7, 113.0, 112.4, 111.8, 79.6, 78.2, 74.8, 28.2, 19.4; MS (ESI) *m/z* Calcd for C₂₇H₂₈N₂O₅ (M⁺): 460.2, Found: 461.1 (M+H⁺).

4-(4-(2-Ethoxy-2-oxoacetamido)-3-isobutoxybenzamido)-3-isobutoxybenzoic acid (21): To an ice-cooled solution of 4-(4-amino-3-isobutoxybenzamido)-3-isobutoxybenzoic acid (**19**; 60 mg, 0.15 mmol, 1 eq) and pyridine (24 μL, 0.30 mmol, 2 eq) in CH₂Cl₂ (7 mL) was added dropwise a solution of ethyl chlorooxoacetate (18 μL, 0.16 mmol, 1.1 eq) in CH₂Cl₂ (1 mL). The reaction mixture was allowed to warm to room temperature and stirred overnight. The resulting precipitate was collected by vacuum filtration, and the product was washed with cold 1 M HCl, cold EtOAc, then dried under high vacuum at 40 °C overnight to furnish the title compound as a white solid (57 mg, 76%): ¹H-NMR (DMSO-d₆, 400 MHz) δ 12.94 (1H, bs, CO₂H), 9.73 (1H, s, NH), 9.43 (1H, s, NH), 8.83 (1H, d, J=3.6 Hz, Ar), 8.23 (1H, d, J=8.0 Hz, Ar), 8.04 (1H, d, J=8.0 Hz, Ar), 7.56 (3H, m, Ar), 7.52 (1H, s, Ar), 4.30 (2H, q, J=6.8 Hz, OCH₂CH₃), 3.95 (2H, d, J=5.2 Hz, OCH₂), 3.87 (2H, d, J=5.6 Hz, OCH₂), 2.10 (2H, m, 2xCH(CH₃)₂), 1.29 (3H, t, J=6.8 Hz, OCH₂CH₃), 1.03 (6H, d, J=6.4 Hz, CH(CH₃)₂), 0.99 (6H, d, J=6.4 Hz, CH(CH₃)₂); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 167.3,

164.5, 160.3, 154.7, 150.0, 148.2, 144.2, 131.7, 131.3, 129.4, 127.6, 126.8, 122.5, 120.8, 119.5, 112.7, 111.1, 75.0, 74.9, 63.3, 28.2, 19.5, 19.3, 14.2; MS (ESI) m/z Calcd for $C_{26}H_{32}N_2O_8$ (M^+): 500.2, Found: 501.1 ($M+H^+$); Anal. Calcd for $C_{29}H_{26}N_2O_7$: C, 62.39; H, 6.44; N, 5.60. Found: C, 62.45; H, 6.25; N, 5.54.

4-(4-(2-(Carboxymethoxy)acetamido)-3-isobutoxybenzamido)-3-isobutoxybenzoic acid (22): To an ice-cooled solution of 4-(4-amino-3-isobutoxybenzamido)-3-isobutoxybenzoic acid (**19**; 60 mg, 0.15 mmol, 1 eq) and Et_3N (42 μ L, 0.30 mmol, 2 eq) in anhydrous THF (7 mL) was added diglycolic anhydride (21 mg, 0.18 mmol, 1.2 eq). The reaction mixture was heated at 50 °C overnight. The resulting white precipitate was collected by vacuum filtration, washing with cold 1 M HCl, cold EtOAc, then dried under high vacuum at 40 °C overnight to deliver the title compound (22 mg, 28%): 1H -NMR (DMSO- d_6 , 400 MHz) δ 12.92 (2H, bs, $2 \times CO_2H$), 9.38 (1H, s, NH), 9.35 (1H, s, NH), 8.34 (1H, d, $J=8.0$ Hz, Ar), 8.06 (1H, d, $J=8.0$ Hz, Ar), 7.57-7.51 (4H, m, Ar), 4.18 (4H, s, $2 \times OCH_2CO$), 3.90 (4H, m, $2 \times OCH_2$), 2.08 (2H, m, $2 \times CH(CH_3)_2$), 0.99 (12H, d, $J=6.4$ Hz, $2 \times CH(CH_3)_2$); ^{13}C -NMR (DMSO- d_6 , 100 MHz) δ 171.5, 168.0, 167.3, 164.5, 149.8, 147.6, 131.8, 130.5, 129.9, 127.5, 122.5, 122.2, 120.7, 118.6, 112.6, 110.8, 75.0, 74.9, 70.7, 68.3, 28.2, 28.1, 19.5, 19.3; MS (ESI) m/z Calcd for $C_{26}H_{32}N_2O_9$ (M^+): 516.2, Found: 517.1 ($M+H^+$).

4-(4-(Carboxyformamido)-3-isobutoxybenzamido)-3-isobutoxybenzoic acid (23): 4-(4-(2-Ethoxy-2-oxoacetamido)-3-isobutoxybenzamido)-3-isobutoxybenzoic acid (**21**; 33 mg, 0.066 mmol, 1 eq) was dissolved in a 3:1:1 mixture of THF/MeOH/ H_2O . $LiOH \cdot H_2O$ (7 mg, 0.17 mmol, 2.5 eq) was added to the reaction mixture, which was stirred at room temperature for 24 h. The reaction was acidified to pH 1–2 with 1N HCl, which generated a white precipitate that was collected by vacuum filtration. The precipitate was washed on the filter with 0.1N HCl, and dried under high vacuum to afford the title compound as a white solid (18 mg, 58%): 1H -NMR (DMSO- d_6 , 400 MHz) δ 12.89 (1H, s, CO_2H), 9.78 (1H, s, NH), 9.41 (1H, s, NH), 8.26 (1H, d, $J=8.8$ Hz, Ar), 8.04 (1H, d, $J=8.8$ Hz, Ar), 7.59-7.56 (3H, m, Ar), 7.52 (1H, s, Ar), 3.94 (2H, d, $J=6.4$ Hz, OCH_2), 3.87 (2H, d, $J=6.0$ Hz, OCH_2), 2.09 (2H, m, $2 \times CH(CH_3)_2$), 1.02 (6H, d, $J=6.0$ Hz, $CH(CH_3)_2$), 0.99 (6H, d, $J=6.4$ Hz, $CH(CH_3)_2$); ^{13}C -NMR (DMSO- d_6 , 100 MHz) δ 167.3, 164.5, 161.8, 156.1, 150.0, 148.1, 131.8, 131.0, 129.7, 127.6, 122.5, 120.8, 119.2, 112.7, 111.1, 75.0, 74.9, 28.2, 28.1, 19.5, 19.3; MS (ESI) m/z Calcd for $C_{24}H_{28}N_2O_8$ (M^+): 472.2, Found: 473.1 ($M+H^+$).

2-(3-Isobutoxy-4-(3-isobutoxy-4-nitrobenzamido)benzamido)acetic acid (26): **24** (28 mg, 0.052 mmol) was dissolved in 20% TFA/ CH_2Cl_2 (2 mL). After stirring at room temperature for 3 h, TLC indicated the reaction was complete. All solvents were removed in vacuo and residual TFA was removed by repeated azeotroping with $CHCl_3$. The residue was dried under high vacuum to deliver the title compound as a sticky, white solid (25 mg, 100%): 1H -NMR (DMSO- d_6 , 400 MHz) δ 12.58 (1H, s, CO_2H), 9.76 (1H, s, NH), 8.83 (1H, s, NH), 7.99 (1H, d, $J=8.0$ Hz, Ar), 7.85 (1H, d, $J=8.8$ Hz, Ar), 7.76 (1H, s, Ar), 7.58 (1H, d, $J=8.8$ Hz, Ar), 7.54 (1H, s, Ar), 7.51 (1H, d, $J=8.0$ Hz, Ar), 4.00 (2H, d, $J=6.4$ Hz, OCH_2), 3.91 (2H, d, $J=5.6$ Hz, $NHCH_2$), 3.85 (2H, d, $J=6.4$ Hz, OCH_2), 2.05 (2H, m, $2 \times CH(CH_3)_2$), 0.96 (12H, m, $2 \times CH(CH_3)_2$); ^{13}C -NMR (DMSO- d_6 , 100 MHz) δ 171.8, 166.2, 163.9, 151.4,

151.1, 141.5, 139.8, 131.8, 129.7, 125.5, 124.1, 120.0, 119.9, 114.2, 111.5, 75.6, 74.9, 41.6, 28.2, 28.0, 19.5, 19.1; MS (ESI) m/z Calcd for $C_{24}H_{29}N_3O_8$ (M^+): 487.2, Found: 488.1 ($M+H^+$).

2,2'-((3-Isobutoxy-4-(3-isobutoxy-4-nitrobenzamido)benzoyl)azanediyl)diacetic acid (27): **25** (36 mg, 0.055 mmol) was dissolved in 20% TFA/ CH_2Cl_2 (2 mL). After stirring at room temperature for 3 h, TLC indicated the reaction was complete. All solvents were removed in vacuo and residual TFA was removed by repeated azeotrope with $CHCl_3$. The residue was dried under high vacuum to deliver the title compound as a sticky, white solid (30 mg, 100%): 1H -NMR (DMSO- d_6 , 400 MHz) δ 12.95 (2H, bs, $2 \times CO_2H$), 9.75 (1H, s, NH), 7.99 (1H, d, $J=8.0$ Hz, Ar), 7.75 (2H, m, Ar), 7.57 (1H, d, $J=8.0$ Hz, Ar), 6.93 (2H, m, Ar), 3.99 (4H, m, $2 \times NCH_2CO$), 3.85 (2H, d, $J=6.4$ Hz, OCH_2), 3.76 (2H, d, $J=6.4$ Hz, OCH_2), 2.01 (2H, m, $2 \times CH(CH_3)_2$), 0.94 (12H, m, $2 \times CH(CH_3)_2$); ^{13}C -NMR (DMSO- d_6 , 100 MHz) δ 171.4, 171.0, 170.6, 168.3, 163.9, 151.4, 141.5, 139.8, 133.3, 128.3, 125.5, 125.0, 119.9, 118.9, 114.2, 110.8, 75.6, 74.8, 66.7, 52.0, 48.3, 46.9, 28.1, 28.0, 19.4, 19.1; MS (ESI) m/z Calcd for $C_{26}H_{31}N_3O_{10}$ (M^+): 545.2, Found: 546.1 ($M+H^+$).

2-Isobutoxy-4-(3-isobutoxy-4-nitrobenzamido)benzoic acid (31): 3-Isobutoxy-4-nitrobenzoic acid⁷⁵ (**6a**) was converted to its corresponding acid chloride according to General Procedure B on a 0.42 mmol scale, then coupled to 4-amino-2-isobutoxybenzoic acid (**30**) according to General Procedure F to deliver the title compound as an off-white solid (120 mg, 66%): 1H -NMR (DMSO- d_6 , 400 MHz) δ 12.31 (1H, s, CO_2H), 10.55 (1H, s, NH), 8.00 (1H, d, $J=8.8$ Hz, Ar), 7.75 (1H, s, Ar), 7.69 (1H, d, $J=8.8$ Hz, Ar), 7.62 (2H, m, Ar), 7.38 (1H, d, $J=8.0$ Hz, Ar), 4.02 (2H, d, $J=6.0$ Hz, OCH_2), 3.76 (2H, d, $J=6.4$ Hz, OCH_2), 2.03 (2H, m, $2 \times CH(CH_3)_2$), 0.97 (12H, m, $2 \times CH(CH_3)_2$); ^{13}C -NMR (DMSO- d_6 , 100 MHz) δ 167.0, 164.6, 159.0, 151.4, 143.6, 141.6, 140.0, 132.4, 125.3, 120.0, 116.6, 114.7, 111.8, 105.1, 75.7, 74.8, 28.2, 28.1, 19.4, 19.1; MS (ESI) m/z Calcd for $C_{22}H_{26}N_2O_7$ (M^+): 430.2, Found: 431.1 ($M+H^+$).

2-Isobutoxy-4-(2-isobutoxy-4-nitrobenzamido)benzoic acid (32): Compound **29** was converted to its corresponding acid chloride according to General Procedure B on a 0.42 mmol scale, then coupled to 4-amino-2-isobutoxybenzoic acid (**30**) according to General Procedure F to deliver the title compound as an off-white solid (102 mg, 57%): 1H -NMR (DMSO- d_6 , 400 MHz) δ 12.28 (1H, s, CO_2H), 10.51 (1H, s, NH), 7.87 (2H, m, Ar), 7.75 (1H, d, $J=8.0$ Hz, Ar), 7.67 (1H, d, $J=8.8$ Hz, Ar), 7.51 (1H, s, Ar), 7.25 (1H, d, $J=8.0$ Hz, Ar), 3.97 (2H, d, $J=6.0$ Hz, OCH_2), 3.73 (2H, d, $J=6.4$ Hz, OCH_2), 2.01 (2H, m, $2 \times CH(CH_3)_2$), 0.97 (6H, d, $J=6.4$ Hz, $CH(CH_3)_2$), 0.92 (6H, d, $J=6.0$ Hz, $CH(CH_3)_2$); ^{13}C -NMR (DMSO- d_6 , 100 MHz) δ 167.0, 164.2, 159.1, 156.6, 149.8, 143.5, 132.6, 132.3, 130.5, 116.3, 115.8, 110.9, 107.9, 104.2, 75.4, 74.7, 28.1, 28.0, 19.3, 19.2; MS (ESI) m/z Calcd for $C_{22}H_{26}N_2O_7$ (M^+): 430.2, Found: 431.1 ($M+H^+$).

3-Isobutoxy-4-(2-isobutoxy-4-nitrobenzamido)benzoic acid (33): Compound **29** was converted to its corresponding acid chloride according to General Procedure B on a 0.42 mmol scale, then coupled to 4-amino-3-isobutoxybenzoic acid⁷⁵ (**8a**) according to General Procedure F to deliver the title compound as an off-white solid (106 mg, 59%): 1H -NMR

(DMSO- d_6 , 400 MHz) δ 12.83 (1H, bs, CO₂H), 10.00 (1H, s, NH), 8.40 (1H, d, J=8.0 Hz, Ar), 8.09 (1H, d, J=8.8 Hz, Ar), 7.96 (1H, s, Ar), 7.92 (1H, d, J=8.0 Hz, Ar), 7.59 (1H, d, J=8.8 Hz, Ar), 7.54 (1H, s, Ar), 4.14 (2H, d, J=6.8 Hz, OCH₂), 3.91 (2H, d, J=6.4 Hz, OCH₂), 2.07 (2H, m, 2xCH(CH₃)₂), 0.92 (12H, m, 2xCH(CH₃)₂); ¹³C-NMR (DMSO- d_6 , 100 MHz) δ 167.2, 162.4, 156.9, 150.5, 148.2, 132.6, 131.6, 128.9, 127.1, 122.8, 120.5, 116.2, 112.8, 109.1, 76.4, 75.3, 27.9, 27.7, 19.3, 19.1; MS (ESI) m/z Calcd for C₂₂H₂₆N₂O₇ (M⁺): 430.2, Found: 431.1 (M+H⁺).

Recombinant proteins and EMSAs—The human c-Myc bHLH-ZIP domain (residues 353–437) and full-length human Max(L) (160 residues) and Max(S) (151 residues) were used for all studies requiring purified proteins. Max(L) and Max(S) arise by alternate splicing and differ only by virtue of a nine amino acid deletion near the N-terminus of the latter that prevents it from binding DNA as a homodimer while still being able to associate with c-Myc and bind DNA as a heterodimer.^{59,60} Recombinant c-Myc bHLH-ZIP, Max(L) and Max(S) were expressed in the *E. coli* strain BL21DE3(plysS)^{38,45,46} as N-terminal His₆-tagged proteins in the pET151-D-TOPO vector. Bacteria were grown at 37°C in L-Broth to an A₆₀₀ $\approx$ 0.8 and then for an additional 16–18 h in the presence of 1 mM isopropyl-L-thio-B-D-galactopyranoside to induce expression of the recombinant proteins. Cultures were harvested, pelleted by centrifugation as 5,000 $\times$ g for 10 min, washed in ice cold PBS and lysed in a buffer containing 8 M urea, 100 mM NaH₂PO₄ and 10 mM Tris-HCl, pH 8.0. Clarified lysates were then applied to Ni-NTA-Agarose affinity chromatography columns (Qiagen, Inc. Chatsworth, CA), which were washed exhaustively in lysis buffer and then developed with a pH gradient according to the directions of the supplier. Fractions containing the highest concentrations of protein were then pooled, dialyzed against 150 mM NaCl, Tris-HCl pH 6.7 and cleaved with TEV protease at 25°C as previously described.^{11,45,75} For larger amounts of protein, the TEV protease:His₆-tagged protein molar ratios were increased to 1:50 and digestions were allowed to proceed for up to 72 h. The cleaved residues containing the His₆ tag were then removed by an additional round of Ni-NTA-Agarose chromatography. Proteins were dialyzed against storage buffer comprised of TrisHCl 50 mM pH 6.3, NaCl 150 mM and 30% glycerol and were then stored in small aliquots at –80°C. SDS-PAGE and Coomassie Blue staining of all purified proteins was performed to verify that purity exceeded 95% in all cases.

EMSA assays were performed as previously described^{37,38,45–49} using 30 nM of each of the above-described purified proteins and 30 nM of a 6-carboxy-2',4,4',5',7,7'-hexachloro-fluorescein (HEX)-tagged double-stranded oligonucleotide containing a c-Myc binding site (IDT, Coralville, IA). Binding reactions contained 1 $\times$ PBS (pH 7.3), 1 mmol/L EDTA, 0.1% NP40, 5% glycerol, 1 mmol/L DTT, and 400 μ g/mL bovine serum albumin. Protein dimerization was allowed to proceed at room temperature for 90 min prior to the addition of the oligonucleotide for an additional 15 min. The entire reaction was subjected to electrophoresis in an 8% polyacrylamide/bis-acrylamide (80:1) gel in 0.5 $\times$ Tris-borate EDTA at 20 °C.

NMR Samples

For NMR studies, which utilized ^{15}N -labeled proteins, proteins were propagated and purified as described above except that the growth medium contained 1 g/L $^{15}\text{NH}_4\text{Cl}$. Uniformly ^{15}N labeled Max(S) and c-Myc (353–437) were dialyzed at 4°C against an identical buffer comprised of 50 mM Tris pH 7.5, 150 mM NaCl, 0.01% sodium azide. The dilute samples of Max(S) and c-Myc were concentrated to 0.43 mM and 0.23 mM, respectively by stirred cell concentration (Millipore MWCO 3000). An NMR sample of Max(S) was formed by combining the ^{15}N labeled Max(S) protein with a buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.01% sodium azide) to a final concentration of 0.153 mM with 10% D_2O . NMR samples of ^{15}N labeled c-Myc–Max(S) were prepared by combining equal molar amounts of the proteins to a final concentration of 0.153 mM with 10% D_2O . Titration using compound **4da** was conducted with addition of small volumes of a stock solution of **4da** in DMSO, reaching a maximum endpoint DMSO concentration of 8%.

NMR Spectroscopy

NMR Experiments were performed on a Bruker Avance 600 MHz spectrometer. A standard $^1\text{H}/^{15}\text{N}$ fast HSQC pulse sequence was used for experiments with the Max/c-Myc proteins at 298K. The chemical shifts were referenced to the $^1\text{H}_2\text{O}$ signal at 4.87 ppm. The NMR data were processed using NMRPipe.⁷⁷ Peak heights were measured using a modified version of Sparky.⁷⁸

Calculation of Dissociation Constants (K_d)—The dissociation constants, K_d , for the binding of **4da** to the c-Myc–Max(S) complex were determined by fitting the change in intensity of the bound and unbound amide crosspeaks to a simple bimolecular association model.⁷⁹

$$C = C_0 + (C_T - C_0)X \left[\frac{Kd + M_T + P_T - \sqrt{(Kd + M_T + P_T)^2 - 4P_T M_T}}{2P_T} \right]$$

In this expression C_0 and C_T are the intensities at the initial and final points of the titration. P_T is the total concentration of the c-Myc–Max(S) complex, and M_T is the total concentration of **4da** at each particular point in the titration. Fitting of the binding data was carried out using Matlab (MathWorks, USA).

Surface plasmon resonance (SPR): Recombinant, N-terminal His₆-tagged c-Myc and Max(S) and Max(L) proteins were expressed in the pET151/D-Topo bacterial expression vectors and purified to >90% homogeneity using nickel-agarose gel chromatography as previously described.^{38,45,48,49} In the case of c-Myc, only an 85 residue bHLH-ZIP domain was expressed whereas, in the case of Max(S) and Max(L), the full-length proteins were expressed. His₆ tags were cleaved with TEV protease and removed with an additional nickel-agarose chromatographic step. The proteins were then dialyzed against PBS (pH 6.5) concentrated by Centriprep Ultracel YM-3 filtration (Millipore, Carrigtwohill, Co. Cork, Ireland) and stored at -80°C in small aliquots. Preliminary studies with these proteins

showed them to be capable of functioning in EMSA experiments as both c-Myc–Max(S) heterodimers and Max(L) homodimers (not shown).

SPR was performed with a Biacore Model 3000 instrument (Biacor, Uppsala, Sweden) employing a streptavidin-coated SA biosensor chip (BR-1000-32) (GE Healthcare Bio-Sciences AB, Pittsburgh, PA). The following biotinylated E-box-containing oligonucleotide (5'-biotin-[TGAAGCAGACCACGTGGTTCGTCCTTCA] was annealed with its unlabeled opposite strand oligonucleotide, diluted in HBS-EP running buffer (0.5M NaCl; 10 mM HEPES, pH 7.4; 3 mM EDTA and 0.005% v/v Surfactant P20) and immobilized on the flow cell to allow the attachment of ~700 RU. A second flow cell without any bound DNA was used as a blank. DNA binding experiments were carried out with running buffer (0.15 M NaCl; 10 mM HEPES, pH 7.4; 3 mM EDTA, 0.005% v/v Surfactant P20 and 5% DMSO) at a flow rate of 60 $\mu\text{L min}^{-1}$.

Binding of pre-formed c-Myc–Max(S) or Max(L)–Max(L) dimers was achieved by first allowing dimerization to occur at a concentration of 20 nM of each protein HBS-EP buffer for 30 min. Dimers were then introduced onto the oligonucleotide-containing chip at a flow rate of 60 $\mu\text{L min}^{-1}$. In each case, the amount of c-Myc–Max(S) heterodimer or Max(L) homodimer binding was found to be linearly proportional to concentration and reached equilibrium at the highest concentration, indicating that binding was both specific and saturable. In all cases, protein concentrations were chosen so as to provide an additional 250 relative response units upon binding to the sensor chip. Under similar conditions, no binding to the immobilized oligonucleotide was seen when c-Myc monomer alone was tested (not shown)).

Small molecule interaction studies were performed either by pre-incubating the molecules at the indicated concentrations for 30 min with c-Myc (20 nM) followed by the addition of Max(S) at the above-noted concentrations. In other experiments, designed to determine whether compounds could perturb the binding of pre-formed c-Myc–Max heterodimers, c-Myc and Max(S) proteins were first allowed to heterodimerize at the above concentrations followed by the addition of compounds to the final stated concentrations for 30 min. The mixture was then passed over the oligonucleotide-bound chip at a rate of 60 $\mu\text{L min}^{-1}$ while maintaining a constant concentration of compound.

Binding constants and graphing were performed with BIAevaluation 4.1.1 software (University of Reading, UK), all response units were normalized to 0–100 RU. More detailed descriptions of these procedures will be published elsewhere (Wang et al, in preparation)

Cell viability assays: These were performed as previously described.^{37,38,47,48,62} Briefly, cells at >90% viability were seeded into 96 well plates (2×10^3 cells/well) in fresh growth medium containing 10-point serial dilutions of the compounds of interest. Incubations were allowed to proceed for three days at which time cell viability was assed using the MTT assay as previously described.^{37,47,48} Each point was assessed in at least triplicate determinations.

Cell cycle analyses: Cell cycle analyses were performed as previously described.³⁷

Briefly, after treating with the indicated c-Myc inhibitors, cells were washed twice in cold PBS and re-suspended in 1 ml of 10 mM NaCl, 10 mM Tris-HCl, (pH 8.0), 0.1% NP40, 10 µg/ml RNase A, and 15 µg/ml propidium iodide (Sigma-Aldrich, Inc. St. Louis, MO). Stained nuclei were analyzed on a Becton Dickinson FACStar fluorescence-activated cell sorter and cell cycle quantification was performed using ModFit LT 3.0 software (Verity Software House, Topsham ME).

Neutral lipid quantification: H460 large cell lung cancer cells were incubated at sub-confluent densities in 6 well plates with the indicated concentrations of c-Myc inhibitors for 48 h. The cells were then washed twice in PBS, trypsinized and again washed twice in PBS before being re-suspended in 0.1 ml of PBS. 0.9 ml of PBS containing 50 µg/ml of BODIPY (4,4-difluoro-3a,4adiaza-s-indacene) 459/503 (Life Technologies, Carlsbad, CA), which is specific for neutral lipid, was then added and the re-suspended cells were incubated for 30 min at ambient temperature. Cells were then washed three additional times in PBS before being re-suspended in 0.5 ml of PBS and analyzed by flow cytometry. Fluorescence quantification was performed using Cell Quest Pro software (BD Biosciences, Franklin Lakes, NJ) and mean fluorescence of each sample was determined.

Luciferase assays: The luciferase expression vector pGL4.28[*luc2CP*/minP/Hygro] (Promega, Inc. Madison, WI) contains a minimal mammalian promoter (minP) and a luciferase2CP expression cassette that imparts additional protein instability by fusing hCL1 and PEST sequences. A large number of additional mutations were also introduced throughout the vector to minimize the non-specific binding of mammalian transcription factors and otherwise reduce background expression. Into a unique XhoI site of the polylinker adjacent to the minP sequence, we ligated one of three individual oligonucleotides containing tandemly triplicated c-Myc binding sites (5'-TCGAGCCACGTGGCCACGTGGCCACGTGGC-3') (Wt-c-Myc), mutant Myc binding sites (5'-TCGAGCCTCGAGGCCTCGAGGCCTCGAGGC-3'), Mut-c-Myc) and NF-κB binding sites (5'-TCGAGGGACTTTCCATGGGACTTTCCATGGGACTTTCC-3') (NF-κB) where underlined bases indicate the relevant transcription factor binding sites. The identities of all constructs were determined by automated Sanger DNA sequencing. Each vector was then combined with a 5-fold excess of the vector pFR400, which encodes a mutant mammalian dihydrofolate reductase with a lower Km for the cytotoxic drug methotrexate⁷⁸ and stably transfected into HeLa cells using Superfect (Qiagen, Valencia, CA). Following selection in hygromycin, stably transfected clones were pooled and subjected to at least two rounds of selection in 4-fold stepwise increasing concentrations of methotrexate (Sigma-Aldrich, St Louis, MO) as previously described to allow for amplification of the adjacent vector sequences.⁷⁸ Cells were cultured continuously in methotrexate until the day of plating for luciferase assays so as to ensure maintenance of the amplified plasmid sequences.

To perform luciferase assays, 10⁶ cells were seeded into 6 well plates. The following day, the medium was removed and fresh medium containing the indicated concentration of c-Myc inhibitor was added for 6 h. Cells were then trypsinized, washed twice in PBS and

pelleted by low-speed centrifugation. An aliquot of each sample was used for protein determinations against which subsequent luciferase determinations were normalized. The remaining cell pellets were lysed and assayed in triplicate in 96 well plates using a ONE-Glo™ Luciferase Assay luciferase assay kit according to the directions of the supplier (Promega). Readings were obtained on a Wallac 1420 VICTOR2 (PerkinElmer Life and Analytical Sciences). Under these conditions, background luciferase activity in cells expressing the Mut-c-Myc vector was indistinguishable from that of untransfected cells whereas the expression of luciferase in control lysates of cells transfected with the Wt-c-Myc and NF-κB vectors was typically 50–100-fold higher. Background values were subtracted from all experimental determinations. All results obtained from cells exposed to c-Myc inhibitors were plotted as mean values $\pm$ 1 standard error and expressed relative to those of untreated cells, which were arbitrarily set at 100%.

Co-immunoprecipitation (co-IP) studies: Co-IP assays were performed as previously described.⁴⁸ Briefly, approximately 5×10^6 HL60 cells were exposed for 6 hr to the stated concentration of c-Myc inhibitor or to the DMSO vehicle only, which served as a negative control. Cells were collected by centrifugation at $500 \times g$ for 10 min, washed twice in ice-cold PBS and lysed in IP Buffer.^{48,60} An aliquot of each cleared lysate was saved prior to co-IP to allow a comparison of input c-Myc protein levels. 300 μ g of the cleared lysate in 1 ml of IP buffer was then precipitated at 4°C overnight with a 1:200 dilution of anti-Max antibody⁶⁰ followed by precipitation with protein G-Sepharose using conditions suggested by the supplier (Santa Cruz Biotechnology, Inc. Santa Cruz, CA). The precipitate was then washed three times in IP buffer and subjected to 10% SDS-PAGE and immunoblotting with a 1:1000 dilution of anti-Myc monoclonal antibody (9E10, Santa Cruz Biotechnology, Santa Cruz, CA). Blots were developed using an enhanced chemiluminescence kit following the directions recommended by the supplier (Pierce ECL Plus, Thermo-Fisher, Pittsburgh, PA).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support of this work was provided by an American Cancer Society Young Investigator Award (S.F.), the University of Maryland School of Pharmacy (S.F.), an American Chemical Society Pre-Doctoral Medicinal Chemistry Fellowship and American Foundation for Pharmaceutical Education Fellowship (both to J.L.Y.), and the National Institutes of Health (R01CA140624 to E.V.P.).

ABBREVIATIONS

BET	bromodomain and extraterminal domain
bHLH-ZIP	basic helix-loop-helix leucine zipper
EMSA	electrophoretic mobility shift assay
HSQC	heteronuclear single quantum coherence
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

PPI	protein–protein interaction
SPR	surface plasmon resonance
TCA	tricarboxylic acid cycle

REFERENCES

1. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. *Mol. Cell Biol.* 1999; 19:1–11. [PubMed: 9858526]
2. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. *Oncogene.* 1999; 18:3004–3016. [PubMed: 10378696]
3. Collier HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, Golub TR. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. *Proc. Natl. Acad. Sci. USA.* 2000; 97:3260–3265. [PubMed: 10737792]
4. Trumpp A, Refaeli Y, Oskarsson T, Gasser S, Murphy M, Martin GR, Bishop JM. c-Myc regulates mammalian body size by controlling cell number but not cell size. *Nature.* 2001; 414:768–773. [PubMed: 11742404]
5. Eisenman RN. Deconstructing myc. *Genes Dev.* 2001; 15:2023–2030. [PubMed: 11511533]
6. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. *Oncogene.* 2001; 20:5595–5610. [PubMed: 11607812]
7. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. *Nat. Rev. Cancer.* 2002; 2:764–776. [PubMed: 12360279]
8. Pelengaris S, Khan M. The many faces of c-MYC. *Arch. Biochem. Biophys.* 2003; 416:129–136. [PubMed: 12893289]
9. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. *Nat. Rev. Mol. Cell Biol.* 2005; 6:635–645. [PubMed: 16064138]
10. Meyer N, Penn LZ. Reflecting on 25 years with MYC. *Nat. Rev. Cancer.* 2008; 8:976–990. [PubMed: 19029958]
11. Nair SK, Burley SK. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. *Cell.* 2003; 112:193–205. [PubMed: 12553908]
12. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. *Cell.* 1993; 72:233–245. [PubMed: 8425220]
13. Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. *Cancer Res.* 1992; 52:1107–1113. [PubMed: 1737370]
14. Buchholz M, Schatz A, Wagner M, Michl P, Linhart T, Adler G, Gress TM, Ellenrieder V. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca²⁺/calcieneurin signaling pathway. *EMBO J.* 2006; 25:3714–3724. [PubMed: 16874304]
15. Mitani S, Kamata H, Fujiwara M, Aoki N, Tango T, Fukuchi K, Oka T. Analysis of c-myc DNA amplification in non-small cell lung carcinoma in comparison with small cell lung carcinoma using polymerase chain reaction. *Clin. Exp. Med.* 2001; 1:105–111. [PubMed: 11699727]
16. Erisman MD, Rothberg PG, Diehl RE, Morse CC, Spandorfer JM, Astrin SM. *Mol. Cell. Biol.* 1985; 5:1969–1976. [PubMed: 3837853]
17. Delgado MD, Leon J. Myc roles in hematopoiesis and leukemia. *Genes Cancer.* 2010; 1:605–616. [PubMed: 21779460]
18. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. *Proc. Natl. Acad. Sci. USA.* 1982; 79:7824–7827. [PubMed: 6961453]
19. von Eyss B, Eilers M. Addicted to Myc--but why? *Genes Dev.* 2011; 25:895–897. [PubMed: 21536730]

20. Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, Gudkov AV, Prochownik EV, Nikiforov MA. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. *Oncogene*. 2008; 27:1905–1915. [PubMed: 17906696]
21. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI. Modelling Myc inhibition as a cancer therapy. *Nature*. 2008; 455:679–683. [PubMed: 18716624]
22. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE. Selective inhibition of BET bromodomains. *Nature*. 2010; 468:1067–1073. [PubMed: 20871596]
23. Muller S, Filippakopoulos P, Knapp S. Bromodomains as therapeutic targets. *Expert Rev. Mol. Med*. 2011; 13:e29. [PubMed: 21933453]
24. Prinjha RK, Witherington J, Lee K. Place your BETs: the therapeutic potential of bromodomains. *Trends Pharmacol. Sci*. 2012; 33:146–153. [PubMed: 22277300]
25. Hewings DS, Rooney TP, Jennings LE, Hay DA, Schofield CJ, Brennan PE, Knapp S, Conway SJ. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. *J. Med. Chem*. 2012; 55:9393–9413. [PubMed: 22924434]
26. Sanchez R, Meslamani J, Zhou MM. The bromodomain: from epigenome reader to druggable target. *Biochim. Biophys. Acta*. 2014; 1839:676–685. [PubMed: 24686119]
27. Zirath H, Frenzel A, Oliynyk G, Segerström L, Westermarck UK, Larsson K, Munksgaard Persson M, Hultenby K, Lehtiö J, Einvik C, Pålman S, Kogner P, Jakobsson PJ, Henriksson MA. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. *Proc. Natl. Acad. Sci. U S A*. 2013; 110:10258–10263. [PubMed: 23733953]
28. Soucek L, Nasi S, Evan GI. Omomyc expression in skin prevents Myc-induced papillomatosis. *Cell Death. Differ*. 2004; 11:1038–1045. [PubMed: 15143346]
29. Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, González-Juncà A, Sodir NM, Massó-Vallés D, Beaulieu ME, Swigart LB, McGee MM, Somma MP, Nasi S, Seoane J, Evan GI, Soucek L. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. *Nat Commun*. 2014; 5:4632. [PubMed: 25130259]
30. Soucek L, Evan GI. The ups and downs of Myc biology. *Curr. Opin. Genet. Dev*. 2010; 20:91–95. [PubMed: 19962879]
31. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastiris E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. *Cell*. 2011; 146:904–917. [PubMed: 21889194]
32. Soucek L, Whitfield JR, Sodir NM, Masso-Valles D, Serrano E, Karnezis AN, Swigart LB, Evan GI. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. *Genes Dev*. 2013; 27:504–513. [PubMed: 23475959]
33. Fletcher S, Prochownik EV. Small-molecule inhibitors of the Myc oncoprotein. *Biochim. Biophys. Acta*. 2014
34. Yap JL, Chauhan J, Jung K-Y, Chen L, Prochownik EV, Fletcher S. Small-molecule inhibitors of dimeric transcription factors: Antagonism of protein–protein and protein–DNA interactions. *Med Chem Comm*. 2012; 3:541–551.
35. Prochownik EV, Vogt PK. Therapeutic Targeting of Myc. *Genes Cancer*. 2010; 1:650–659. [PubMed: 21132100]
36. Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. *Oncogene*. 2003; 22:6151–6159. [PubMed: 13679853]
37. Wang H, Hammoudeh DI, Follis AV, Reese BE, Lazo JS, Metallo SJ, Prochownik EV. Improved low molecular weight Myc-Max inhibitors. *Mol. Cancer Ther*. 2007; 6:2399–2408. [PubMed: 17876039]
38. Berg T, Cohen SB, Desharnais J, Sonderegger C, Maslyar DJ, Goldberg J, Boger DL, Vogt PK. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of

- chicken embryo fibroblasts. *Proc. Natl. Acad. Sci. USA*. 2002; 99:3830–3835. [PubMed: 11891322]
39. Shi J, Strover JS, Whitby LR, Vogt PK, Boger DL. Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. *Bioorg. Med. Chem. Lett.* 2009; 19:6038–6041. [PubMed: 19800226]
40. Xu Y, Shi J, Yamamoto N, Moss JA, Vogt PK, Janda KD. A credit-card library approach for disrupting protein-protein interactions. *Bioorg. Med. Chem.* 2006; 14:2660–2673. [PubMed: 16384710]
41. Kiessling A, Sperl B, Hollis A, Eick D, Berg T. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. *Chem. Biol.* 2006; 13:745–751. [PubMed: 16873022]
42. Kiessling A, Wiesinger R, Sperl B, Berg T. Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. *Chem Med Chem.* 2007; 2:627–630. [PubMed: 17315254]
43. Follis AV, Hammoudeh DI, Wang HB, Prochownik EV, Metallo SJ. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. *Chem. Biol.* 2008; 15:1149–1155. [PubMed: 19022175]
44. Hammoudeh DI, Follis AV, Prochownik EV, Metallo SJ. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. *J. Am. Chem. Soc.* 2009; 131:7390–7401. [PubMed: 19432426]
45. Yap JL, Wang H, Hu A, Chauhan J, Jung K-Y, Gharavi RB, Prochownik EV, Fletcher S. Pharmacophore identification of c-Myc inhibitor 2. *Bioorg. Med. Chem. Lett.* 2013; 23:370–374. [PubMed: 23177256]
46. Wang H, Chauhan J, Hu A, Pendleton K, Yap JL, Sabato PE, Jones JW, Perri M, Yu J, Cione E, Kane MA, Fletcher S, Prochownik EV. Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 2. *Oncotarget.* 2013; 4:936–947. [PubMed: 23801058]
47. Chauhan J, Wang H, Yap JL, Sabato PE, Hu A, Prochownik EV, Fletcher S. Discovery of methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-Max dimerization. *Chem Med Chem.* 2014; 9:2274–2285. [PubMed: 24976143]
48. Fieber W, Schneider ML, Matt T, Kräutler B, Konrat R, Bister K. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc. *J. Mol. Biol.* 2001; 307:1395–1410. [PubMed: 11292350]
49. Ernst JT, Kutzki O, Debnath AK, Jiang S, Lu H, Hamilton AD. Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. *Angew. Chem. Int. Ed. Engl.* 2002; 41:278–281. [PubMed: 12491408]
50. Saraogi I, Hebda JA, Becerril J, Estroff LA, Miranker AD, Hamilton AD. Synthetic alpha-helix mimetics as agonists and antagonists of islet amyloid polypeptide aggregation. *Angew. Chem. Int. Ed. Engl.* 2010; 49:736–739. [PubMed: 20029853]
51. Yap JL, Cao X, Vanommeslaeghe K, Jung K-Y, Wilder P, Nan A, MacKerell AD Jr, Smythe WR, Fletcher S. Relaxation of the rigid backbone of an oligoamide-foldamer-based α -helix mimetic: identification of potent Bcl-xL inhibitors. *Org. Biomol. Chem.* 2012; 10:2928–2933. [PubMed: 22395339]
52. Cao X, Yap JL, Newell-Rogers MK, Peddaboina C, Hua J, Papaconstantinou HT, Jupiter D, Rai A, Jung K-Y, Tubin RP, Yu W, Vanommeslaeghe K, Wilder PT, MacKerell AD Jr, Fletcher S, Smythe WR. The novel BH3 α -helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak. *Mol. Cancer.* 2013; 12:42. [PubMed: 23680104]
53. Jung K-Y, Vanommeslaeghe K, Lanning ME, Yap JL, Gordon C, Wilder PT, MacKerell AD Jr, Fletcher S. Amphipathic α -helix mimetics based on a 1,2-diphenylacetylene scaffold. *Org. Lett.* 2013; 15:3234–3237. [PubMed: 23763721]
54. Orner BP, Ernst JT, Hamilton AD. Toward proteomimetics: Terphenyl derivatives as structural and functional mimics of extended regions of an α -helix. *J. Am. Chem. Soc.* 2001; 123:5382–5383. [PubMed: 11457415]

55. Plante JP, Burnley T, Malkova B, Webb ME, Warriner SL, Edwards TA, Wilson AJ. Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction. *Chem. Commun.* 2009;5091–5093.
56. Lanning ME, Fletcher S. Recapitulating the α -helix: nonpeptidic, low-molecular-weight ligands for the modulation of helix-mediated protein–protein interactions. *Future Med. Chem.* 2013; 5:2157–2174. [PubMed: 24261892]
57. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. *Science.* 1991; 251:1211–1217. [PubMed: 2006410]
58. Zhang H, Fan S, Prochownik EV. Distinct roles for MAX protein isoforms in proliferation and apoptosis. *J. Biol. Chem.* 1997; 272:17416–17424. [PubMed: 9211884]
59. Prochownik EV, VanAntwerp ME. Differential patterns of DNA binding by myc and max proteins. *Proc. Natl. Acad. Sci. U. S. A.* 1993; 90:960–964. [PubMed: 8430110]
60. Holien T, Vatsveen TK, Hella H, Waage A, Sundan A. Addiction to c-MYC in multiple myeloma. *Blood.* 2012; 120:2450–2453. [PubMed: 22806891]
61. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. *Cell Growth Differ.* 1997; 8:1039–1048. [PubMed: 9342182]
62. Graves JA, Rothermund K, Wang T, Qian W, Van Houten B, Prochownik EV. Point mutations in c-Myc uncouple neoplastic transformation from multiple other phenotypes in rat fibroblasts. *PLoS One.* 2010; 5(10):e13717. [PubMed: 21060841]
63. Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. *J. Clin. Invest.* 1994; 93:820–828. [PubMed: 8113414]
64. Arvanitis C, Felsher DW. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. *Semin. Cancer Biol.* 2006; 16:313–317. [PubMed: 16935001]
65. Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, Gudkov AV, Prochownik EV, Nikiforov MA. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. *Oncogene.* 2008; 27:1905–1915. [PubMed: 17906696]
66. Dang CV. Therapeutic targeting of Myc-reprogrammed cancer cell metabolism. *Cold Spring Harb. Symp. Quant. Biol.* 2011; 76:369–374. [PubMed: 21960526]
67. Graves JA, Wang Y, Sims-Lucas S, Cherok E, Rothermund K, Branca MF, Elster J, Beer-Stolz D, Van Houten B, Vockley J, Prochownik EV. Mitochondrial structure, function and dynamics are temporally controlled by c-Myc. *PLoS One.* 2012; 7:e37699. [PubMed: 22629444]
68. Li F, Wang Y, Zeller KI, Potter JJ, Wonsey DR, O'Donnell KA, Kim JW, Yustein JT, Lee LA, Dang CV. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. *Mol. Cell. Biol.* 2005; 25:6225–6234. [PubMed: 15988031]
69. Edmunds LR, Sharma L, Kang A, Lu J, Vockley J, Basu S, Uppala R, Goetzman ES, Beck ME, Scott D, Prochownik EV. c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate. *J. Biol. Chem.* 2014
70. Rahl PB, Lin CY, Seila AC, Flynn RA, McQuine S, Burge CB, Sharp PA, Young RA. c-Myc regulates transcriptional pause release. *Cell.* 2010; 141:432–445. [PubMed: 20434984]
71. Clausen DM, Guo J, Parise RA, Beumer JH, Egorin MJ, Lazo JS, Prochownik EV, Eiseman JL. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 2, a novel small-molecule inhibitor of c-Myc/Max dimerization. *J. Pharmacol. Exp. Ther.* 2010; 335:715–727. [PubMed: 20801893]
72. Murphy NS, Prabhakaran P, Azzarito V, Plante JP, Hardie MJ, Kilner CA, Warriner SL, Wilson AJ. Solid-phase methodology for synthesis of O-alkylated aromatic oligoamide inhibitors of α -helix-mediated protein-protein interactions. *Chem. Eur. J.* 2013; 19:5546–5550. [PubMed: 23508712]
73. Plante J, Campbell F, Malkova B, Kilner C, Warriner SL, Wilson AJ. Synthesis of functionalised aromatic oligamide rods. *Org. Biomol. Chem.* 2008; 6:138–146. [PubMed: 18075658]
74. Ferre-D'Amare AR, Prendergast GC, Ziff EB, Burley SK. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain. *Nature.* 1993; 363:38–45. [PubMed: 8479534]

75. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. *J. Biomol. NMR.* 1995; 6:277–293. [PubMed: 8520220]
76. Goddard, TD.; Kneller, DG. SPARKY3. San Francisco, CA: University of California; 2001.
77. Lian LY, Barsukov IL, Sutcliffe MJ, Sze KH, Roberts GC. Protein-ligand interactions: exchange processes and determination of ligand conformation and protein-ligand contacts. *Meth. Enzymol.* 1994; 239:657–700. [PubMed: 7830601]
78. Prochownik EV, Kukowska J. Deregulated expression of c-myc by murine erythroleukaemia cells prevents differentiation. *Nature.* 1986; 322:848–850. [PubMed: 3528863]

BRIEFS

Synthetic α -helix mimetics perturb the c-Myc–Max dimer, abrogating its ability to bind DNA.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1.

A. A generic α -helix mimetic designed to recognize the Arg₃₆₆–Arg₃₇₈ region of c-Myc in the helical c-Myc–Max heterodimer. R¹ and R² are hydrophobic groups, such as isobutyl and benzyl (see Scheme 1). Bubbles with two sets of residues indicate side chains targeted (outside parentheses) at the c-Myc–Max interface in late stage complex assembly and (inside parentheses) at the HLH region of c-Myc in the c-Myc–Max complex. **B.** Chemical structure of **4da** (“JKY-2-169”). **C.** Putative binding mode of compound **4da** indicating the region of the c-Myc–Max PPI to be targeted by synthetic α -helix mimetics (PDB ID: 1NKP). The

binding site was delineated by Arg₃₇₂, Phe₃₇₄, Leu₃₇₇ and Arg₃₇₈. **D.** Zoom-in of binding mode. Computational modeling was achieved with Molegro Virtual Docker. Figure 1B was generated with PyMOL: red = c-Myc; blue = Max; green = DNA; cyan, coloured by atom type = c-Myc residues interacting significantly with ligand; yellow, coloured by atom type = **4da** (“JKY-2-169”).

Figure 2.

A, C, E, G, I, K: c-Myc-Max(S) EMSA assays for synthetic α -helix mimetics. Recombinant c-Myc₃₅₃₋₄₃₇ and full-length Max(S), which does not bind DNA as homodimers,⁵⁹⁻⁶¹ were purified to homogeneity from *E. coli* and used at a final concentration of 30 nM; B, D, F, H, J, L: control experiments showed that none of the compounds significantly affected DNA binding by Max(L)-Max(L) homodimers, which bind DNA well. Each figure is representative of three independent trials (Supplementary Figure 1).

Figure 3.

A) ¹⁵N-Max(S) HSQC spectra with (red) and without (black) the addition of 100 μM **4da**; B) ¹⁵N-c-Myc HSQC spectra with (red) and without (black) the addition of 100 μM **4da**; C) heterodimeric complex of ¹⁵N-Max(S) (black alone) and with c-Myc (red); D) the c-Myc-¹⁵N-Max(S) binary complex (black) with the addition of 100 μM of **4da** (red); E) dose response curves of four isolated NMR cross-peak intensities (108.98/8.35, 109.37/8.02, 123.96/7.63, 133.38/7.992 [¹⁵N ppm / ¹H ppm]). (Analysis was performed based on Equation 1 (NMR Experimental Section)).

Figure 4.

SPR analysis of **2** and **4da**. Concentrations refer to (A) c-Myc-Max(S) dimer or (B)–(E) small-molecule ligand. (A). Concentration-dependent binding of c-Myc-Max(S) heterodimers to a biotin-tagged E-box-containing double-stranded oligonucleotide immobilized to a streptavidin-coated biosensor chip. Binding of the oligonucleotide itself was associated with a response of 700–800 units. After resetting this value to baseline, equimolar concentrations of c-Myc and Max(S) were allowed to dimerize for 30 min and then passed over the biosensor chip. Note the concentration-dependent increase in response. (B). Prevention of heterodimerization by **2**. The indicated concentrations of **2** were incubated with 20 nM of c-Myc for 20 min followed by the addition of 20 nM Max(S). Following an additional 30 min incubation, the mixture was applied to the E-Box-containing biosensor chip. (C). DNA binding by pre-formed c-Myc-Max(S) heterodimers is relatively resistant to **2**. Pre-formed c-Myc-Max(S) heterodimers (20 nM of each protein) were incubated for 30 min. with the indicated concentrations of **2** and then applied to the E-Box-containing biosensor chip. (D). Disruption of DNA binding by **4da**. The experiment was performed as described in (B) except that the indicated concentrations of **4da** were incubated with c-Myc monomer prior to the addition of Max(S). (E). The experiment was performed as described in (D) except that pre-formed c-Myc-Max(S) heterodimers were incubated with the indicated concentrations of **4da**. Blue bars indicate the period during which protein-compound mixtures were being injected. Note that the relative response in each case has been normalized to 100 to denote the maximal response for each set of curves

in order to allow inter-group comparisons. Similar results for each panel were obtained on at least two additional occasions.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 5.

4da promotes cell cycle arrest. Logarithmically growing HL60 promyelocytic leukemia cells were incubated with the indicated concentrations of **4da** or the previously described c-Myc inhibitor 10058-F4³⁷ for 24 h. Cells were then collected and stained with propidium iodide as previously described.⁷¹ Typical results are shown. Repeat experiments performed in triplicate on a separate occasion yielded very similar findings (Supplementary Table 1).

Figure 6.

4da causes neutral lipid accumulation. H460 large cell lung cancer cells were incubated in the indicated concentrations of **2** or **4da** for 48 h and then stained with the neutral lipid-specific fluorescent dye BODIPY-459/503.⁷¹ Control, untreated cells were stained in parallel. Curves depict the fluorescence distribution of at least 10^4 individual events from each group. The numbers in the upper left corner depict the ratio of mean fluorescence intensity of inhibitor-treated cells to control cells, based on the average of biological triplicates stained in parallel $\pm$ one standard error. Typical flow diagrams are indicated in each panel.

Figure 7.

4da specifically inhibits a c-Myc reporter vector. HeLa cells stably expressing luciferase vectors under the control of a minimal promoter bearing c-Myc or NF-κB binding sites were exposed to the indicated concentrations of **4da** or the previously well-characterized c-Myc inhibitor **2** for 6 h. Cells were assayed for luciferase activity as described in the Experimental Section. The results depicted represent the mean of triplicate determinations $\pm$ 1 standard error with the value for untreated cells arbitrarily being set to 100%.

Figure 8.

4da fails to promote c-Myc–Max dissociation *in situ*. HL60 promyelocytic leukemia cells were exposed for 6 h the indicated concentrations of 10058-F4 or **4da** or to DMSO vehicle alone. Total cell lysates were then prepared as previously described⁴⁸ and Max proteins were immunoprecipitated (IP) followed by immunoblotting (IB) of the precipitate with an anti-c-Myc antibody. The bottom portion of each panel shows the total amount of c-Myc protein in lysates prior to IP.

Scheme 1.

(a) R^1OH or R^2OH , NaH, THF, RT, 0 °C to RT, 2 h; (b) $(COCl)_2$, cat. DMF, CH_2Cl_2 , RT, 2 h; (c) H_2 , 10% Pd/C, EtOH, RT, 1–5 h; or $SnCl_2 \cdot 2H_2O$, EtOAc, 50 °C, 3 h; (d) $SOCl_2$, MeOH, 60 °C, 6 h; or MeI, K_2CO_3 , DMF, RT, 4 h.

Scheme 2.

(a) Isobutanol, NaH, THF, RT, 0 °C to RT, 4 h; (b) Bu₃SnCH=CH₂, Pd(PPh₃)₄, toluene, 110 °C, 5 h; (c) KMnO₄, H₂O/acetone, RT, 6 h; (d) (COCl)₂, cat. DMF, CH₂Cl₂, RT, 2 h; (e) SnCl₂·2H₂O, EtOAc, 50 °C, 3 h.

Scheme 3.

(a) *N,N*-dimethylaniline, acetone, RT, 0 °C to RT, 16 h.

16 (X = Y = N, R² = isobutyl)

4aa (X = Y = CH, R² = isobutyl)

4ea (X = Y = CH, R² = 2,3-dihydro-1H-inden-2-yl)

18 (X = Y = N, R² = isobutyl)

19 (X = Y = CH, R² = isobutyl)

20 (X = Y = CH, R² = 2,3-dihydro-1H-inden-2-yl)

Scheme 4.

(a) H₂, 10% Pd/C, EtOH, RT, 1–5 h.

Scheme 5.

(a) ClCOOEt, pyridine, CH₂Cl₂, 0 °C to RT, 16 h; or diglycolic anhydride, Et₃N, DIPEA, 50 °C, 16 h; (b) LiOH.H₂O, THF/MeOH/H₂O, 3:1:1, 24 h, RT.

Scheme 6.

(a) Glycine *tert*-butyl ester•HCl or di-*tert*-butyliminodiacetate, HBTU, DIPEA, DMF, RT, 16 h; (b) 20% TFA/ CH_2Cl_2 , RT, 3 h.

Scheme 7.

(a) Isobutyl iodide, K_2CO_3 , DMF, 50 °C, 16 h; (b) NaOH, THF/MeOH/H₂O, 3:1:1, RT, 1 h; (c) H₂, 10% Pd/C, EtOH, RT, 16 h.

10058-F4 (1)

10074-G5 (2)

JY-3-094 (3)

Chart 1.
Structures of some inhibitors that bind monomeric c-Myc.

Table 1

EMSA screening analysis of abilities of synthetic α -helix mimetics to disrupt the c-Myc–Max/DNA complex at 100 μ M (n = 1). For these experiments, we used the 151 residue isoform of Max, which we term Max(S), which binds DNA only in heterodimeric association with c-Myc and not as a homodimer.⁶⁰ The last column

refers to the amount of DNA binding obtained in the presence of the compound relative to that obtained in its absence. See Experimental Section for further information.

Code Number	R ¹	R ²	R ³	c-Myc-Max/DNA (% relative to control)
4aa			—OH	0
4bb			—OH	47
4da ("JKY-2-169")			—OH	0
14aa			—OMe	112
14ba			—OMe	70
14be			—OMe	109
14ca			—OMe	75
14ce			—OMe	112
14da			—OMe	109
14ea			—OMe	90

Table 2

EMSA-based screening results of the disruption of c-Myc-Max(S)/DNA binding at 100 μ M of synthetic α -helix mimetic (n = 1).

Code Number	R ³	R ⁴	R ⁵	c-Myc-Max/DNA (% relative to control)	Code Number	R ³	R ⁴	R ⁵	c-Myc-Max/DNA (% relative to control)
4ac				104	4ja				90
4ag				116	4jj				87
4ah				75	14bc				73
4ai				87	14cc				85
4aj				81	14dc				88
4ca				0	14de				117
4ea				65	14ec				78
4ff				94	14ee				100
4ga				100					

Table 3

EMSA-based screening results of the disruption of c-Myc-Max(S)/DNA binding at 100 μ M of synthetic α -helix mimetic ($n = 1$). R^4 and R^5 groups located at the 3-positions of the aryl rings unless otherwise stated with a (2), indicating the group is at the 2-position.

Code Number	X	Y	Z	R ³	R ⁴	R ⁵	c-Myc-Max/DNA (% relative to control)
15	N	CH					0
16	N	N					0
17	CH	CH					97
18	N	N					79
19	CH	CH					105
20	CH	CH					87
21	CH	CH					0
22	CH	CH					89
23	CH	CH					99
26	CH	CH					107
27	CH	CH					99
32	CH	CH					80
33	CH	CH					96
34	CH	CH					120

Table 4

EMSA-determined disruption of ternary c-Myc–Max(S)/DNA and Max(L)–Max(L)/DNA complexes by synthetic α -helix mimetics. Each IC_{50} and standard error were calculated based on three independent EMSAs performed for each compound concentration tested (Supplementary Figure 1).

Code Number	Inhibition (IC_{50} , μM)	
	c-Myc-Max(S)/DNA	Max(L)-Max(L)/DNA
4aa	20.2 ± 1.3	84.9 ± 12.0
4da	11.6 ± 2.3	>20
4ca	43.0 ± 1.7	79.0 ± 8.5
15	43.8 ± 2.9	>100
16	23.8 ± 2.7	68.7 ± 4.5
21	5.6 ± 0.7	>12.5

Table 5

Viability of HL60 and Daudi cells in the presence of synthetic α -helix mimetics after 3 days. MTT cell proliferation assays performed as previously described.^{37,38,45,48,49} The results shown represent the means and standard deviations of quadruplicate experiments.

Code Number	Inhibition (IC ₅₀ , μ M)	
	HL60 Cells	Daudi Cells
4aa	39.9 $\pm$ 5.3	22.9 $\pm$ 2.5
4da	19.9 $\pm$ 1.6	9.5 $\pm$ 0.7
4ca	44.8 $\pm$ 0.9	25.6 $\pm$ 1.4
15	21.5 $\pm$ 2.7	11.2 $\pm$ 1.4
16	30.3 $\pm$ 4.6	11.1 $\pm$ 1.1
21	>50	>50

Table 6

Growth inhibition studies were performed as described for Table 3. Cells were incubated in serial dilutions of **4da** for 3 days before determining viable cell numbers relative to untreated cells.

Cell Line or Strain	Cell Type	Inhibition (IC ₅₀ , μ M)
H460	lung cancer	15.9 $\pm$ 1.1
HeLa	uterine cervical cancer	10.8 $\pm$ 0.8
HEK-293	embryonic kidney	10.4 $\pm$ 1.3
JJN3	myeloma	15.7 $\pm$ 0.9
INA-6	myeloma	18.1 $\pm$ 0.8
IH-1	myeloma	20.6 $\pm$ 1.1
ANBL-6	myeloma	35.6 $\pm$ 2.6
KJON	myeloma	23.0 $\pm$ 2.6
U266	myeloma	46.0 $\pm$ 3.2
HO15.19 (<i>myc</i> ^{-/-})	rat fibroblasts	20.6 $\pm$ 1.0
HO15.19-wt-Myc	rat fibroblasts	14.1 $\pm$ 1.2